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1 
Hepatitis C infection               
 
The hepatitis C virus and its discovery  
The hepatitis C virus (HCV) is a small enveloped single-stranded RNA virus of positive 
polarity with liver tissue tropism. It belongs to the Hepacivirus genus and is a member of 
the Flaviviridae1. Until 1975, only two hepatitis viruses were known, but 65% of post-
transfusion hepatitides were not caused by hepatitis A or B2. However, non-A non-B 
hepatitis was thought to be caused by an infectious agent as inoculation of a chimpanzee 
with serum of a patient with non-A non-B hepatitis was followed by a rise in liver enzymes 
3,4 and this presumed infectious agent could be inactivated with chloroform5. Due to new 
cloning techniques for nucleic acid, in 1989 the genome of non-A non B hepatitis from an 
infected chimpanzee was characterized with cDNA, hence the name HCV6.  
 
Prevalence and genotype distribution world wide 
It is estimated that globally 71 million people are living with HCV. Although HCV affects all 
global regions, major differences exist between and within countries. The most affected are 
the  Eastern Mediterranean Region and European Region, with a prevalence of 2.3% and 
1.5% respectively7,8. Of the hepatitis C genome from different regions, at least 7 different 
genotype are known (>30% difference between two nucleotide sequences). This may be 
further divided into at least 67 subtypes within these genotypes (20-25% difference 
between two nucleotide sequences)9,10 and this number will probably rise as in the future 
even more samples will be sequenced.  
 
Parenteral exposure as risk factor for hepatitis C transmission 
Hepatitis C is a blood born virus which can be transmitted by parenteral exposure to blood 
and blood products11,12, haemodialysis13, non-sterile needles (nosocomial, intra-venous 
drug use, tattooing14-16) or infected transplant organs17,18. Due to screening of blood 
products the risk of acquiring hepatitis C through blood transfusion is now estimated to be 
as low as 1:500.000 to 1:1.000.00019. Transplant organizations now have strategies for HCV 
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screening. However, nosocomial HCV outbreaks in developed countries are still reported, 
for example through the re-use of contaminated syringes (despite using a new needle), the 
improper use of multidose vials used for multiple patients and in haemodialysis units20. 
Healthcare workers, especially those who come in close contact with infected patients and 
sharp objects, are at risk for HCV acquisition. However the incidence of seroconversion 
after exposure to an HCV positive source is estimated to be less than 2%16 and a Dutch 
single-hospital cohort study showed that the prevalence among its healthcare workers 
(1/729; 0.14%) was not higher than that of the general population21. Another study showed 
that people with multiple tattoos and/or piercings in the Netherlands seem not to be at 
increased risk for HCV infections, as the authors did not find an increased seroprevalence in 
this risk group22.  
 
Intravenous drug use (IVDU) is one of the most important risk factors for parenteral HCV 
acquisition as was shown by the high prevalence of HCV in this population23. However, the 
development of opioid substitution therapy (OST) and needle syringe exchange programs 
(NSP) have been shown to firmly reduce the risk of HCV acquisition24. In the Netherlands 
most IVDU use took place during the sixties to the nineties and nowadays good OST and 
NSP have been implemented. However, in regions without proper preventive measures like 
OST and NSP, HCV transmission via IVDU remains an important health care problem25.  
 
Sexual transmission of hepatitis C 
A large prospective cohort study showed that in serodiscordant (HCV discordant) 
monogamous heterosexual couples the long-term transmission risk was 0.001% or lower26. 
Interestingly, a relatively new subgroup of hepatitis C patients started to emerge last 
century. The first reports on sexually transmitted HCV infection in men who have sex with 
men  (MSM) who denied IVDU started to merge in 2004 and 200527-29. Sexual transmission 
of HCV in HIV-positive MSM will be described in more detail on pages 19 and 20. 
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1 
Acute hepatitis C infection 
Patients who become infected with hepatitis C virus can develop abnormal laboratory 
findings in the following order: detectable HCV RNA, then elevation in ALT, followed by HCV 
antibodies30. After inoculation there is a variable incubation period depending on 
transmission mode. High level viremia occurs usually within 1-2 weeks after inoculation in 
transfusion hepatitis cases, needle stick injuries or experimentally inoculated 
chimpanzees31-33. However, it is unknown if this can be extrapolated to low-inoculum 
infections. Fluctuation in HCV RNA levels has been reported as a hallmark of the viral 
dynamics in the early stages of HCV infection and some patients may even become 
temporarily HCV RNA negative34-37. There is a considerable heterogeneity among 
individuals, as some patients may show quite high HCV RNA levels, some patients may 
show spontaneous clearance beyond six months or have a large HCV RNA decline during 
acute HCV infection without spontaneous clearance34. Within 40-50 days after high level 
viremia, ALT levels will start to rise, showing that there is some degree of liver cell 
injury31,38. The elevation of aminotransferases varies greatly between individuals. High ALT 
levels seem to be correlated with seroconversion31,38, however, in some patients, especially 
in HIV-coinfected patients, seroconversion can be delayed. In a series with 43 HIV-positive 
patients with acute HCV infection, after three months 37% of patients still had a negative 
antibody test. After 9 months, 10% of patients still had a negative antibody test39. In fact, 
some patients stay undetectable for antibodies for years40.  
 
Acute hepatitis is most often asymptomatic, most patients do not develop icterus and 
fulminant hepatitis is rare. A study that was designed to include symptomatic patients 
infected with HCV, reported non-specific symptoms like jaundice, influenza like symptoms, 
dark urine, discoloured stools, nausea and discomfort in the right upper quadrant of the 
abdomen41. However, due to the subclinical course of HCV infection,  and the fact that 
symptoms of an acute HCV infection are non-specific, it is important to screen high risk 
groups. Case definitions for acute hepatitis C virus infection vary considerably between 
studies42.  
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There is a lack of evidence on when ‘acute’ infection becomes ‘chronic’ especially since the 
precise timing of infection is usually problematic. Acute HCV is often defined as the 
somewhat arbitrarily chosen period of the initial 6 months following exposure, in other 
words, the phase of the infection with fluctuating ALT and HCV RNA and the time window 
in which spontaneous viral clearance can occur34. However, this phase may last much 
longer in some patients 43 and a large multinational acute HCV cohort study showed that 
34%, 67%, and 83% of patients demonstrated clearance at resp. 3, 6, and 12 months44. A 
consensus definition was created by the European AIDS Treatment Network (NEAT) acute 
hepatitis C infection consensus panel in 2011 and is shown in table 145.  
 
 
 
 
 
 
 
 
Table 1 Consensus definitions acute hepatitis C infection NEAT 45 
 
Preferred criteria 
 
(1) Positive anti-HCV immunoglobulin G (IgG) in the presence or absence of a positive HCV-RNA 
and a documented negative anti-HCV IgG in the previous 12 months. 
(2) Positive HCV-RNA and a documented negative HCV-RNA and negative anti-HCV IgG in the 
previous 12 months. 
 
Alternative criteria       if tests in the past year are lacking 
 
Positive HCV-RNA regardless of anti-HCV IgG with any of the following two conditions: 
(a) An acute rise in ALT greater than 10 times the ULN. 
(b) An acute rise in ALT greater than five times the ULN, with documented normal ALT within 12 
months.  
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1 
Chronic hepatitis C  
The hallmark of HCV is its ability to establish persistent (chronic) infection, which occurs in 
approximately 75% of cases46. Persistence of HCV is probably multifactorial and arises from 
the combination of an inadequate human immune response in combination with the 
immune evasive character of the HCV virus itself47,48. In cohort studies, spontaneous 
clearance of hepatitis C seemed to be associated with female gender, younger age, 
symptomatic acute HCV infection, interleukine-28 B CC genotype, HCV genotype 1 and a 
high peak HCV RNA level44,46,49,50. For HIV-coinfected patients, several studies have shown 
that the rate of spontaneous clearance is significantly lower — in the range of 10 to 
20%49,51. If a patient does not spontaneously clear the virus, chronic hepatitis C infection 
will develop. In chronically infected patients, persistent hepatic inflammation can lead to 
cirrhosis in 10-20% of patients over 20-30 years. Once cirrhosis has developed there is a 1–
5% annual risk of HCC and a 3–6% annual risk of hepatic decompensation52,53.  
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Treatment of hepatitis C with direct-acting antivirals    
 
Since the discovery of HCV, there has been a revolution in hepatitis C treatment options 
and efficacy of HCV therapy. Sustained virological response has improved from 2-7% for 
interferon monotherapy from the 90ties onwards to as high as 98% for the second 
generation DAA combination therapies. This revolution coincides with the unravelling of 
the structure and function of hepatitis C and its proteins which led to the development of 
the direct-acting antivirals54. However, most HCV clinical trials are single arm studies 
without randomization, almost no head to head trials have been executed and study 
populations are difficult to compare due to different ethnical and socioeconomic 
backgrounds and different routes of HCV transmission. The proteins involved in HCV 
polyprotein processing, HCV RNA replication and virion assembly are a target for therapy 
and will be discussed in this paragraph.  
 
Structural and functional analysis of the hepatitis C virus 
For a long time, the analysis of hepatitis C was difficult as serum-derived virus is not easily 
ultra-filtered because of its association with low-density lipoproteins55-57. Furthermore, a 
cell culture for hepatitis C replication did not exist. It has taken a decade after the discovery 
of its genome in 1989 before the first research on non-infectious hepatitis C virus 
replication in the human hepatoma cell line Huh7 was possible58. Another 15 years were 
needed to visualize cell free virions with cryo-electron and negative-stain transmission 
electron microscopy59,60 and to develop an efficient infectious cell culture system which 
allowed functional assays for treatment targets59. Viruses isolated from cell cultures have a 
spherical shape with a diameter around 50-55 nm. Using 3D modelling of the HCV-like 
particles and genomic comparison with other Flavivirusses, it was assumed that 90 copies 
of a block of two heterodimers of HCV proteins E1 and E2 forms the outer layer of the 
virions with an diameter of approximately 50 nm. Two viral glycoproteins, E1 and E2, are 
embedded in the lipid envelope. This outer layer surrounds a lipid bilayer that contains the 
viral nucleocapsid consisting of the HCV core protein that contains the genomic viral RNA60. 
The HCV genome has a length of approximately 9.6 kb. The single strand RNA genome of 
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1 
this virus is 9100 nucleotides long, a single open reading frame that encodes for 10 
proteins, 3 structural proteins and 7 non-structural proteins of which NS3/4A, NS5A and 
NS5B are targeted today with direct-acting antiviral therapy54.  
 
The hepatitis C NS3/4A proteins  
The N-terminus of the NS3 protein has serine protease activity and requires interaction 
with NS4A to cleave the rest of the downstream polyprotein61. The HCV NS3/4A protein 
also cleaves MAVS which blocks RIG-I signalling and prevents IFN induction in response to 
viral infection62. Both functions make NS3/4A an attractive target for inhibition therapy. 
The location of the active side of NS3/4A protease (a shallow groove) made  de design of 
compound inhibitors quite difficult63, but today both macrocyclic and linear tetra-peptide-
based α-ketoamide derivates have been developed which inhibit the NS3/4A protein. 
 
The hepatitis C NS5A protein  
The NS5A protein has multiple functions in HCV replication, viral assembly and virion 
release. Although the action of NS5A inhibitors is not based on blocking enzymatic activity 
and the exact mechanism of action is still not clear64, NS5A inhibitors were shown to be 
highly potent.  
 
The hepatitis C NS5B protein  
The NS5B protein is an RNA-dependent RNA-polymerase65. It is positioned in the ER 
membrane with the active sides of the polymerase located in the cytoplasm. It is an 
important compound of the HCV replication complex situated in the NS4B-induced 
membranous web66. The cytosolic part of this viral enzyme forms a right-handed connected 
structure with a palm, fingers and a thumb65. Nucleoside analogue polymerase inhibitors 
(like sofosbuvir) are built into the RNA chain causing chain termination67. As the active side 
of the NS5B protein is highly conserved, nucleoside inhibitors are potentially pan-genotypic 
and have a high barrier to resistance. Non-nucleoside analogue polymerase inhibitors (like 
dasabuvir) bind to allosteric enzyme sites which results in conformational protein change68.  
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Direct-acting antiviral therapy 
Direct-acting antiviral therapy should be prescribed according to the genotype of the 
patient as most but not all currently used regimens are pan-genotypic69. Furthermore, 
different classes of DAA’s should always be combined as resistance will appear promptly 
under most DAA monotherapies70. Due to the extremely high replication rate of HCV and 
the error prone polymerase enzyme which lacks proofreading, many quasispecies (HCV 
variants) arise within one patient soon after infection71 harbouring resistance associated 
variants (RAS). Both, naturally occurring polymorphisms 72, and drug-induced RAS can be 
detected. Drug-induced RAS with a relative higher fitness compared to wild-type virus can 
emerge during treatment and result in treatment failure73.  
 
In the case of therapy failure and the emergence of drug-induced RAS, some types of these 
RAS can revert back to wild type, while others do not or to a lesser extent. In general, NS5A 
RAS persist longer than NS3 RAS, as NS5A RAS can stay detectable >96 weeks after 
treatment74-76. Most direct-acting antivirals are only available as co-formulations and 
combining individual compounds often is much more expensive. In the fall of 2017, the 
termination of the further clinical development of two new DAA’s was announced77,78. This 
may mark the end of an unprecedented era of DAA development.  
Currently approved and recommended DAA’s for the treatment of chronic HCV in the 
Europe and the Netherlands are: NS3 protease inhibitors: paritaprevir,  grazoprevir, 
voxilaprevir and glecaprevir; NS5A inhibitors: ledipasvir, ombitasvir, daclatasvir, elbasvir, 
velpatasvir and pibrentasvir; NS5B polymerase inhibitors: sofosbuvir and dasabuvir69,79-81. 
 
Sofosbuvir (Solvaldi®) and daclatasvir (Daklinza®) are available as individual compounds, the 
other DAA’s are only available as combination tablets: 
 sofosbuvir/ledipasvir 1 tablet once daily (Harvoni®) registered for genotypes 1, 3, 6; 
 grazoprevir/elbasvir 1 table once daily (Zepatier®) registered for genotypes 1, 4; 
 sofosbuvir/velpatasvir 1 tablet once daily (Epclusa®) registered for genotypes 1-6;  
 glecaprevir/pibrentasvir 3 tablets once daily (Maviret®) registered for genotypes 1-6;  
 sofosbuvir/ledipasvir/voxilaprevir 1 tablet once daily  (Vosevi®)80,81 registered for 1-6. 
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1 
Hepatitis C elimination          
 
Due to the rapidly evolving field, we have made hepatitis C a curable disease for almost all 
patients in a time span of 30 years, from its discovery in 1989 until today54. However, if an 
infectious disease is curable, this does not automatically mean that it is possible to 
eradicate, eliminate or even control this disease. It is important to distinguish these three 
definitions. ‘Eradication’ is defined as permanent reduction to zero of the worldwide 
incidence, ‘elimination’ as reduction to zero of the incidence of infection caused by a 
specific agent in a defined geographical area and ‘control’ as the reduction of disease 
incidence, prevalence, morbidity or mortality to a locally acceptable level82.  
In 2016 the World Health organization released a global health sector strategy on viral 
hepatitis which is part of the 2030 Agenda for Sustainable Development. One of these goals 
is striving towards the elimination of HCV as a public health threat, and this is defined as a 
90% reduction in new HCV infections (incidence) and a 65% reduction of HCV-related 
deaths (mortality) by 2030. Priority actions in the plan to reach these hepatitis C 
elimination impact targets are : 
- development of an information system to understand the hepatitis C epidemic and 
focus the response on the countries specific epidemic;  
- define high-impact interventions on the continuum of care and hepatitis C services;  
- strengthen the delivery of these services to achieve maximum impact and equality; 
- propose strategies to reduce costs; 
- and promote innovation to drive rapid progress83. 
 
Barriers for hepatitis C elimination are that only few countries have national hepatitis plans 
embracing the points described above, national data on epidemics can be lacking and (key) 
populations are hidden or marginalized, thereby increasing vulnerability and preventing 
equal access to services. The continuum of hepatitis C care should be tailored to the 
specific epidemic within a country to curb the epidemic in order to reach the elimination 
goals. Furthermore, effective interventions should be combined and tailored for the 
specific population, location and setting. In the next paragraph the hepatitis C epidemic in 
the Netherlands in general and, more specific, in Dutch HIV-positive MSM will be described.  
Chapter 1 
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Hepatitis C in the Netherlands        
 
Who are at risk for hepatitis C in the Netherlands 
The exact total prevalence of HCV in the Netherlands is not known. This may be explained 
by the fact that data were derived from measuring either HCV RNA in blood or anti-HCV 
antibodies in a random sample of the Dutch population or measuring anti-HCV antibody 
prevalence in specific risk groups. From 1995 to 2014, 220 HCV RNA positive samples were 
found in a cohort of 868,095 new (first time) unpaid blood donors (prevalence 0.03%). The 
highest prevalence was found in 1999 and gradually declined thereafter. However, this 
number is probably an underestimation as in the Netherlands persons with (self-reported) 
risk behaviour for HIV infections are actively excluded from blood donation84. In the 
PIENTER-2 study, cross-sectional serum samples were collected from the Dutch population 
via municipal registers between 2006-2007. In this study, a large sample of most prevalent 
migrant groups in the Netherlands was included (as they were underrepresented in earlier 
studies). In total, 14 out of 4446 samples were anti-HCV positive (0.30%; 95% C.I. 0.05-
0.55%), with a prevalence of 0.17% (95% C.I. 0.00-0.36%) for indigenous Dutch inhabitants 
and 2.12% (95% C.I. 0.46-3.78%) for first generation migrants from endemic countries.  
 
However, the number of HIV-positive MSM and persons reporting IVDU were small in this 
study85. In 2013, Vriend et al. reported on the combined outcomes of Dutch prevalence 
studies for HCV in the general population as well as in specific risk groups (migrants, MSM 
and people who inject drugs) to estimate the Dutch HCV prevalence. The estimated 
national seroprevalence of HCV was 0.22%  (min 0.07%, max 0.37%)86. Besides these cross-
sectional data, other studies gave more insight into the longitudinal incidence of hepatitis C 
infections in IVDU en HIV-positive MSM in the Netherlands during the last two decades. In a 
retrospective cohort study from Amsterdam that ran from 1985 to 2005, the HCV incidence 
dropped significantly among IVDU23. Meanwhile, the incidence of HCV in HIV-positive MSM 
increased (which will be discussed at page 20)87-90. 
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Screening for hepatitis C in the Netherlands  
On the first of November 2016, the health counsel of the Netherlands released a report on 
the screening of hepatitis C91. They advised against a nationwide screening of all Dutch 
inhabitants, due to the low overall HCV prevalence in the Netherlands. Instead they advised 
case finding, by screening for HCV in specific risk groups, such as first-generation 
migrants/refugees from endemic countries (with endemic being defined as ≥2% HCV 
prevalence), (former) people who inject drugs (most IVDU use dates from 1960-1990) 
whom due to longstanding NSP and OST are most probably already reintegrated in society, 
MSM (‘testing the HIV-positive and at least monitor the HIV-negative’92,93). Furthermore, 
they advised retracing of patients who were previously diagnosed with HCV infection but 
got lost to follow up before curation of HCV. Because of lack of studies on the efficiency of 
screening in the Dutch setting, there are no cost-effectiveness analysis on screening (and 
sub sequential treatment) for HCV for these different risk groups.  
 
Regarding MSM, further recommendations on screening can be found in the following 
guidelines. The Dutch National HIV Guideline from the ‘Nederlandse Vereniging voor HIV 
Behandelaren’ advises to screen all new HIV patients for HCV with HCV antibodies upon 
entry into HIV care and screen sexually active HIV-positive MSM annually with HCV 
antibodies94. Furthermore, the Dutch National Institute for Public Health and the 
Environment’s (RIVM) guideline on sexual health for STI clinics advises  screening for 
hepatitis C with HCV antibodies in HIV  positive  MSM, MSM notified  for  being exposed to 
HCV and MSM diagnosed with a lymphogranuloma venereum infection regardless of HIV 
status  and  MSM refusing an HIV test95.  
 
The hepatitis C epidemic in Dutch HIV-positive men who have sex with men 
For the remaining part of this thesis, we will primarily focus on the hepatitis C epidemic in 
HIV-positive MSM. In 2004 and 2005 the first publications on possible sexual transmission 
of HCV in HIV-positive MSM appeared as hepatitis C unexpectedly started to emerge as a 
sexually transmitted disease in this population27-29,96. Evolutionary analysis of MSM-specific 
HCV strains showed that HCV had possibly been introduced into the MSM network before 
Chapter 1 
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1996-2000, but the vast expansion started only after the nineties, coinciding with the 
widespread introduction of HAART97-99. Epidemics in HIV-positive MSM were seen globally 
in high income countries, such as Europe, the USA, Canada, Australia, Taiwan and 
China100,101. For most low income countries data on the prevalence of HCV in HIV positive 
MSM are scarce, but the prevalence of an actively replicating HCV infection in HIV-infected 
patients in Africa seems to be much lower than estimated before7,102. However, since HIV-
positive MSM are often not recognized as a key population in low income countries, data 
are lacking for this specific high risk population. 
 
For the Netherlands, cohort studies among HIV-positive MSM in Amsterdam showed that 
the HCV incidence in this population rose from 1995 onwards, with a peak around 2005-
2008 and a stabilizing high incidence around 12/1000 PYFU afterwards87-89. However, the 
epidemic in Dutch HIV-positive MSM was not limited to the Dutch capital as HCV infections 
were reported from all over the Netherlands103,104. Moreover, phylogenetic studies have 
shown that local outbreaks in Europe were part of a European transmission network of 
MSM-specific HCV lineages with mainly genotype 1a and 4 infections, which did not overlap 
with strains circulating in IVDU networks99. In contrast, acute HCV infections in HIV-positive 
MSM in the USA and Australia showed limited overlap with the European network and in 
Australia mainly genotype 1a and 3a were showing an overlap with IVDU networks99,105,106.  
 
The specific pathophysiological reason why HCV emerged as a sexually transmitted 
infection in this key population is not exactly clear. Hepatitis C is secreted in sperm107 and 
risk factors for permucosal transmission of the virus like (traumatic) sexual practices and 
ulcerating sexually transmitted infections seem to be independently associated with acute 
HCV infection. In one of the first case-control studies into sexual risk behaviour for HCV 
infection, cases reported more sexual partners, more group sex, more receptive and 
insertive unprotected anal intercourse, a higher percentage of use of toys and fisting and 
cases were more likely to have shared drugs via a nasal or anal route  108. In two more 
recent case-control studies in the Netherlands and Belgium, receptive unprotected anal 
intercourse, douching before anal intercourse, sharing sex toys, unprotected fisting, 
injecting drugs, sharing straws when snorting drugs and a documented gonorrhoea or 
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chlamydial infection in the 6-12 months before study entry, were independently associated 
with HCV acquisition109,110.  
 
In this thesis, we will look at the current HCV epidemic among HIV-positive MSM in the 
Netherlands and discuss different strategies to reduce the transmission of HCV within this 
population. We will specifically use this epidemic to investigate and discuss the possibility 
of micro-elimination within this key population as the Dutch HIV positive MSM population 
is well-defined and regularly screened for HCV infection. 
 
Aims and outline of this thesis        
 
The overall aim of the research described in this thesis is to investigate and discuss possible 
strategies and barriers for micro-elimination of HCV among Dutch HIV-positive MSM in the 
era of DAA.  
 
In part A of this thesis focuses on the effectivity of two interventions which could 
contribute to combating hepatitis C towards its elimination as a public health threat: the 
shortening of direct-acting antiviral therapy for chronic hepatitis C infection as well as for 
acute hepatitis C infection. Shortening of therapy can lead to an improved compliance and 
a reduction of costs which is one of the WHO’s priority actions to reach the hepatitis C 
elimination targets. Moreover, if DAA’s are effective during the acute phase of hepatitis C 
infection, treating high risk patients during the acute phase of infection can reduce (sexual) 
transmission of HCV to others, thereby reducing the HCV incidence in this key population.  
 
In Chapter 2, the effectivity of 8 weeks of ledipasvir/sofosbuvir for chronic genotype 4 
hepatitis C infected direct-acting antiviral-naive HIV-positive and -negative patients without 
cirrhosis is evaluated. Chapter 3 investigates whether grazoprevir/elbasvir is effective when 
given during the acute phase of HCV and whether treatment duration can be shortened 
during the acute phase of an HCV infection without loss of effectiveness.  
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Part B of this thesis focuses on the effects of two recent developments on the hepatitis C 
epidemic among Dutch HIV-positive MSM, as they are a well-defined key population and 
frequently monitored for hepatitis C infection. Besides the strategies which could 
contribute hepatitis C elimination among Dutch HIV-positive MSM as described in part A, in 
this part we also discuss the effects of: the recent unrestricted availability of direct-acting 
antivirals for chronic HCV infection and the introduction of HIV pre-exposure prophylaxis.  
 
In Chapter 4, the treatment uptake and treatment success of direct-acting antiviral hepatitis 
C therapy in HIV-positive patients in the Netherlands is investigated. Chapter 5 focuses on 
the acute hepatitis C incidence before and after the unrestricted availability of direct-acting 
antiviral for chronic hepatitis C among Dutch HIV-positive MSM.  
 
Chapter 6  describes the acute hepatitis C infections among HIV-negative MSM who exhibit 
sexual high risk behaviour and/or use HIV pre-exposure prophylaxis.  
 
Finally, in part C of this thesis the possibility of micro-elimination of HCV among Dutch HIV-
positive MSM in the era of direct-acting antivirals is discussed. In Chapter 7 the possibility of 
hepatitis C elimination among people living with HIV is discussed. Finally, Chapter 8 
summarizes the results of this thesis and future perspectives for HCV elimination of HCV 
among Dutch HIV-positive MSM in the era of DAA’s are discussed.  
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Introduction           
 
In contrast to genotype 1, genotype 4 hepatitis C (HCV) infections are more often found in 
Central Africa and the Middle East with the highest prevalence in Egypt 1. As the initial 
budget impact of HCV treatment with direct-acting antivirals (DAAs) can be substantial for 
countries with a high HCV prevalence2, shortening treatment duration could help in 
reaching WHO’s HCV elimination goals3 by lowering costs and expanding access4. The most 
recent EASL guideline suggests 8 weeks of therapy with sofosbuvir/ledipasvir (SOF/LDP) as 
an option for treatment-naive non-cirrhotic patients with chronic HCV of the genotypes 1a 
and 1b5. 
 
Although the first clinical trials with DAA’s were primarily focused on HCV genotype 1 
infections, the advent of pan-genotypic DAA’s give us the opportunity to study new 
treatment options and even treatment shortening for genotype 4 infections4. Indeed, LDV 
showed a high potency in a study that assessed the phenotypic susceptibility of various 
genotype 4 subtypes6 and in the study that led to the registration of 12 weeks of SOF/LDV 
for genotype 4, 41 of the 44 (93%) patients had a sustained virological response (SVR)7. 
Given the very comparable cure rates after 12 weeks of SOF/LDP for genotype 1 and 4, a 
treatment duration of 8 weeks may be appropriate for genotype 4 as well8. Recently, this 
approach was studied in Egyptian patients and a cure rate of 95% (41/43) was observed in 
the 43 patients9. However, these patients were HIV-negative and because genotype 4a is 
the most prevalent HCV subtype in Egypt, these results cannot be translated to other 
genotype 4 subtypes1.  
 
We evaluated the effectiveness of 8 weeks SOF/LDP for genotype 4 HCV-infected DAA-
naive HIV-positive and -negative patients without cirrhosis in a single arm prospective open 
label study in 10 centers in the Netherlands and Belgium and found a high effectiveness 
these patients.  
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Methods            
 
Design & subjects  
This study was designed as a single arm prospective open label multicenter study in HIV 
and/or hepatitis C treatment centers in the Netherlands (n=9) and Belgium (n=1). Eligible 
participants were HIV positive or negative adults (≥18 years), chronically infected with 
genotype 4 HCV with a screening HCV RNA load <10 million IU/mL. A chronic hepatitis C 
infection was defined according to the EASL guideline as the presence of both anti-HCV 
antibodies and HCV RNA for more than 6 months10. Patients with an eGFR < 30 mL/min or a 
history of DAA treatment failure for the current episode of HCV infection were excluded. 
Only patients with a liver biopsy with a METAVIR score lower than AxF4 or a liver stiffness 
measurement (Fibroscan®) <12.5 kPa were eligible11. Biopsy or shear wave elastography 
results were allowed to be 24 months old. However, in case of METAVIR score F3 or shear 
wave elastography result >9,5 kPa11, results could not be older than 12 months. All 
concomitant co-medication (e.g. cART) was reviewed for drug-drug interactions with the 
Hepatitis Drug Interactions tool of the University of Liverpool12 and co-medication was 
changed if needed before DAA initiation.  
 
Treatment & assessments  
All subjects received 8 weeks of SOF/LDP 90/400 mg QD. HCV RNA loads during therapy 
were analyzed according to local hospital policy, but at least at baseline and week 20 
(SVR12). Because SOF/LDP is already EMA-approved, there was no mandatory reporting of 
minor side effects during this study, but serious adverse events were registered.  
 
Primary outcome and secondary outcomes 
The primary efficacy outcome was the sustained virological response 12 weeks after the 
end of the 8 week therapy (SVR12) in the on-treatment (OT) study population. SVR12 was 
defined as an HCV RNA below the limit of detection 12 weeks or later after the end of 
therapy. The OT population was defined as all patients that had completed the 8-week 
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course and of which a HCV RNA was measured at ≥12 weeks after the end of therapy. 
Secondary outcomes included SVR12 in the intention-to-treat (ITT) population defined as all 
patients that initiated study drugs, SVR12 in the HIV positive compared to the HIV-negative 
population and  SVR12 in the study population with baseline viral loads < 6 million IU/ml 
HCV RNA. 
 
Treatment failures  
HCV relapse was defined as reoccurrence of the HCV virus with which the patient was 
infected at the start of therapy after treatment discontinuation and after the 
documentation of a previously undetectable HCV RNA during therapy. However, as 
reinfection is frequently observed in HIV+ MSM13 and, in 2017, approximately 35% of all 
acute HCV infections in Dutch and Belgian HIV+ MSM were of the genotype 414, it is 
important to differentiate reinfection from relapse because an HCV reinfection should not 
be considered therapy failure. Therefore, in patients with a presumed HCV relapse, a 
genotype analysis with a reverse hybridizing assay (the Versant® HCV Genotype 2.0 System 
(LiPA)) was performed to differentiate relapse with a new HCV genotype from reinfection. If 
genotype 4 was again present at the time of the presumed relapse, a phylogenetic analysis 
was done using a fragment of the envelope E2 gene which includes the hypervariable 
region 1, to differentiate relapse from a genotype 4 reinfection according to the methods 
described by Thomas et al.15. Patients with a documented HCV reinfection 12 weeks after 
the end of therapy were not considered as treatment failures in the analysis. 
 
Sample size  
Although the study was a non-randomized single arm study and therefore not a formal 
non-inferiority randomized clinical trial, we estimated the appropriate sample size for the 
study by calculating the sample size under the assumption that the cure rate with 8 weeks 
of SOF/LDP would be 95% and therefore identical to what was observed after 12 weeks of 
SOF/LDP for chronic HCV genotype 4 in the NIAID SYNERGY16 and the 1119 study17 .  Our 
hypothesis is that we can shorten therapy duration to 8 weeks without a loss of effectivity. 
Therefore we anticipate that the SVR after 8 weeks of therapy is a fixed 95%. We based our 
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95% estimate on the available results on the treatment of genotype 4 with 12 weeks of 
sofosbuvir/ledipasvir at the time the protocol was written in 2016; the NIAID SYNERGY 
study16. In both studies combined, an SVR was observed in  61 of the 65 patients (94%) but 
to be on the conservative site in our sample size calculation we used a fixed 95% SVR as 
comparator. We use a non-inferiority margin of 10%, which means that the lower 95% C.I. 
of the difference between the proportion of patients with an SVR in the intervention group 
and the fixed SVR of 95% should not exceed 10% (e.g. if the SVR result is 95% the difference 
between proportions is 0% and the 95% CI of this 0% should not exceed 10%). For the study 
to have 90% power to show non-inferiority under our study hypothesis, and using an alfa 
error of 5% a sample size of 41 is needed. (Settings are therefore 1-beta of 0,9, alfa 5%, 
true proportion 0,95, null hypothesis proportion 0,95 and delta 0.1.18)  
 
Note: Although we intended to include 41 patients, as a result of the rapid treatment 
uptake of DAAs in HIV-infected MSM in the Netherlands and Belgium19, the inclusion of 
additional patients was not possible because after the screening of 63 and the treatment of 
40 HCV genotype 4 patients (of whom 30 were HIV co-infected), no eligible patients were 
left in any of the participating centers.  
 
Interim analysis and statistical analysis 
A single interim safety analysis was planned and performed after 10 patients had reached 
the SVR12 evaluation endpoint. The stopping rule in the protocol said that the study would 
be discontinued if <8 of the first 10 patients had an SVR12 because the upper limit of the 
95% C.I. of an SVR12 of 7/10  is 89% and with current DAA therapies we considered a 
SVR12 <90% as unacceptably low. Data was analyzed using IBM SPSS statistics® v21. 
Baseline characteristics between HIV-negative and HIV-positive patients were compared 
with Fisher's exact test for categorical variables and 2-sided Mann-Whitney U test for 
continuous variables. A 2-sided p<0.05 was regarded as significant. For the primary as well 
as the secondary endpoints, the proportion of patients with SVR12 was calculated with a 2-
sided C.I. using the exact Clopper-Pearson confidence intervals.  
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Ethics statement 
The protocol was approved by all local medical ethics committees and registered in the 
Dutch Trial Register ‘Nederlands Trial Register’ (Trial ID NTR5729). All subjects signed 
informed consent. 
 
 
 
 
 
 
Figure 1. Flow diagram. 
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Results            
 
From January 2016 until June 2017, 63 patients were screened for eligibility of which 44 
were enrolled. Four patients never started therapy and 30 HIV-positive and 10 HIV-negative 
patients started treatment (figure 1). All patients completed the 8 weeks of therapy but 1 
HIV-negative patient was lost to follow up before the SVR could be evaluated (last HCV viral 
load <15 IU/ml). In the on-treatment population, 33 of the 39 patients were HCV RNA 
negative 12 weeks after therapy and 6 were HCV RNA positive. However, 4 of them had a 
proven reinfection (figure 2). These 4 patients were all MSM and had ongoing unprotected 
sex, underlining the urgent need for effective interventions to decrease the risk of 
reinfection in this subpopulation. In total, 37 of 39 patients (95%; 95% CI 83-99%) of the 
on-treatment population were successfully treated for the HCV virus  that was present at 
baseline. Stratified to HIV-status, 28 of the 30 HIV-positive patients (93%; 95% CI 80-99%) 
and 9 of the 9 HIV-negative patients (100%) reached SVR12 (p=1.0) (table 1). In the 2 
treatment failures the baseline HCV viral loads were 9.8E5 and 8.7E6 IU/mL. The subtype 
was 4c in one patient, but in the other patient the subtype was not typable. No resistance 
associated mutations in NS5a or NS5b were detected at the time of HCV relapse. 
 
Discussion and conclusion         
 
As a result of the rapid treatment uptake of DAAs in HIV-infected MSM in the Netherlands 
and Belgium19, the inclusion of additional patients was not possible because after the 
screening of 63 and the treatment of 40 genotype 4 patients, no eligible patients were left 
in any of the participating centers. Therefore, we did not reach the intended sample size of 
41 patients as stated in the protocol of our study (as described supplement 1). However, 
although relatively small, our sample size was comparable to the number of patients 
included in phase III trials of SOF/LDP that led to the registration of 12 weeks SOF/LDP 
therapy for HCV genotype 45.  
Our study showed that 8 weeks of LPD/SOF could be an effective therapy for non-cirrhotic 
HCV genotype 4 infected patients with a HCV RNA load <10 million IU/ml and is the first to 
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evaluate the efficacy of 8 weeks of SOF/LDP in a substantial number of HIV-coinfected 
patients. Our results further strengthen the observation made among Egyptian mono-
infected patients9. Therefore, 8 weeks of SOF/LDP could be considered a treatment option 
in DAA-naïve genotype 4 patients without cirrhosis, thereby expanding access to therapy to 
a larger number of patients. 
 
 
 
 
 
 
Table 1, part 1. Baseline characteristics according to HIV-status. 
 
MSM: men who have sex with men. IVDU: intra-venous drug use. HCV: hepatitis C virus. cART: combined 
antiretroviral therapy. OT: on-treatment. NA: not applicable.aT-test. bFisher’s exact test. c2-sided Mann 
Withney U test. dReinfections are not considered treatment failure. e2-sided Clopper Pearsons 
confidence interval.  
  All 
(n=40) 
HIV-positive 
(n=30) 
HIV-negative 
(n=10) 
p-value 
Baseline characteristics  
Age (years)a Mean +-SD 51 (+-9.9) 51 (+-10.4) 51 (+-8.7) p=0.971 
Maleb %, n 85% (34/40) 86,7% (24/30) 80% (8/10) p=1.000  
Caucasianb %, n 80% (32/40) 76,7% (23/30) 90% (9/10) p=0.653  
Transmission mode HCVb    
 
p=0.068  
MSM %, n 52.5% (21/40) 63.3% (19/30) 20% (2/10)  
IVDU %, n 12.5% (5/40) 10% (3/30) 20% (2/10)  
Other %, n 7.5% (3/40) 6.7% (2/30) 10% (1/10)  
Missing %, n 27.5% (11/40) 20% (6/30) 50% (5/10)  
Previous treatmentb     
 
p=0.011 
Naive (no treatment) %, n 80% (30/40) 83,3% (25/30) 70% (7/10)  
Peg-interferon +- 
ribavirin 
%, n 20% (8/40) 16.7% (5/30) 30% (3/10) 
 
Baseline viral load 
 (IU/mL)c 
Median + IQR 
1.05 E6  
(3.36 E5 - 3.64 
E6) 
1.21 E6  
(3.97 E5 –  
3.37 E6) 
6.9 E5  
(1.75 E5 –  
2.00 E6) 
 
p=0.235 
Time since diagnosis of 
HCV infection (years)c 
Median + IQR 4.2 (2.1-9.8) 4.4 (2.8-10.1) 4.4 (4.0-4.9) 
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Table 1, continued. Baseline characteristics and outcome according to HIV-status. 
 
MSM: men who have sex with men. IVDU: intra-venous drug use. HCV: hepatitis C virus. cART: combined 
antiretroviral therapy. OT: on-treatment. NA: not applicable.aT-test. bFisher’s exact test. c2-sided Mann 
Withney U test. dReinfections are not considered treatment failure. e2-sided Clopper Pearsons 
confidence interval.  
  All 
(n=40) 
HIV-positive 
(n=30) 
HIV-negative 
(n=10) 
p-value 
Baseline characteristics  
HCV Subtypeb     p=0.304 
4a %, n 15% (6/40) 10% (3/30) 30% (3/10)  
4c %, n 2.5% (1/40) 3.3% (1/30) 0%  
4d %, n 37.5% (15/40) 40% (12/30) 30% (3/10)  
4t %, n 2.5% (1/40) 0% 10% (1/10)  
Unknown %, n 42.5% (17/40) 46.6% (14/30) 30% (3/10)  
Liver stiffness measurement  
(Fibroscan®)  
   
 
pKac median + IQR 5.6 (4.5-7.6) 5.3 (4.2-6.8) 8.8 (6.5 – 10.8) 
 
p=0.004 
 
f3 (>9.5 kPa)b %, n 15% (6/40) 3.3% (1/30) 50% (5/10) p=0.002 
CD4 cell count  (cells/μl) 
Nadir 
at start of HCV therapy 
 
Mean +-SD 
Mean +-SD 
 
NA 
NA 
 
397.9+-53.9 
807.0+-69.0 
 
NA 
NA 
 
On cART %, n NA 100% (30/30) NA  
HIV viral load <40 
copies/ml at start of 
HCV therapy 
%, n NA 97% (29/30) NA 
 
Outcomes in on-treatment populationd  
Effectiveness OT population  
%, n 
95% exact CIe 
 
95% (37/39) 
83-99% 
 
93% (28/30) 
80-99% 
 
100% (9/9) 
- 
 
HCV RNA negative 12 weeks after therapy 33 24 9  
HCV RNA positive 12 weeks after therapy     
Reinfection  
(genotype switch) 
 
Reinfection  
(phylogenetically distinct genotype 4 virus) 
 
Relapse 
1 
 
 
3 
 
2 
1 
 
 
3 
 
2 
- 
 
 
- 
 
- 
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Figure 2. Evolutionary relationships of patients infected with HCV genotype 4. 
Phylogenetic tree of genotype 4 sequences, including relapsers and patients with a reinfection with the 
same genotype before and after treatment. Relapsers are presented by filled symbols in red and 
reinfections are presented by filled symbols in blue. Each patient is presented by a unique symbol. The 
date in the labels indicate sampling dates. The evolutionary history was inferred using the Neighbor-
Joining method20. The optimal tree with the sum of branch length = 1.30658013 is shown. The 
percentage of replicate trees in which the associated taxa clustered together in the bootstrap test 
(10000 replicates) are shown next to the branches21. The tree is drawn to scale, with branch lengths in 
the same units as those of the evolutionary distances used to infer the phylogenetic tree. The 
evolutionary distances were computed using the Maximum Composite Likelihood method22 and are in 
the units of the number of base substitutions per site. The analysis involved 35 nucleotide sequences. All 
ambiguous positions were removed for each sequence pair. There were a total of 427 positions in the 
final dataset. Evolutionary analyses were conducted in MEGA623. 
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Research in context          
 
Evidence before this study and added value of this study 
To identify clinical trials regarding direct-acting antivirals for acute hepatitis C we searched 
PubMed for clinical trials using the search terms ‘hepatitis C’ and ‘acute’ and published 
since 2008 as well as the trial registries clinicaltrials.gov and clinicaltrialsregister.eu and 
conference abstracts of all major hepatology and HIV conferences. We excluded clinical 
trials with interferon-based regimens. The first clinical trials with 6 or 12 weeks of 
sofosbuvir and ribavirin for acute hepatitis C genotype 1 showed only moderate results 
with cure rates between 32-59%. More recently, trials with 6 to 8 weeks of combination 
DAA therapy for acute hepatitis C showed cure rates between 77-100%. However, given 
the low number of patients in each of the studies (n=20-30) and the fact that almost all 
patients were infected with genotype 1 only, no definite conclusions could be drawn. To 
our knowledge, the DAHHS2 study is the first study that included a sufficient number of 
patients (n=80) to demonstrate that a short 8-week regimen of grazoprevir and elbasvir is 
an effective therapy for patients with an acute hepatitis C of both the genotypes 1 and 4. 
Indeed, 99% of the patients were cured which is comparable to the success observed when 
a longer (12 weeks) treatment is given to patients with chronic hepatitis C infection of the 
same genotypes. 
 
Implications of all available evidence 
In specific populations at risk of onward hepatitis C transmission to others (e.g. 
transmission to sex partners in men having sex with men or to needle sharing partners in 
people who inject drugs) being able to start curative hepatitis C therapy immediately after 
the diagnosis of an acute hepatitis C infection will not only prevent transmission to others 
but will lead to direct (shorter treatment duration is possible) and indirect (new infections 
prevented) cost savings. As our study shows that treatment of hepatitis C infection with 
grazoprevir and elbasvir is effective in the acute phase of infection, this treatment strategy 
should be considered in populations with a high risk of onward hepatitis C infection.  
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Abstract            
 
Background  
Direct-acting antivirals effectively cure chronic HCV but definite data on their efficacy when 
used during the acute phase of HCV infections are lacking. In patients at continued risk of 
transmitting HCV to others, being able to treat acute HCV immediately after diagnosis will 
prevent onward transmission. We studied grazoprevir/elbasvir (G/E) as acute HCV therapy 
to evaluate its efficacy and to prove that treatment can be shortened during 
the acute phase of infection. 
  
Methods 
Single-arm prospective trial on the treatment of acute HCV in 15 centres in the Netherlands 
and Belgium (NCT0260032). Patients (≥18 years) were included if they had an acute HCV 
genotype 1 or 4 infection that was ≤26 weeks old. Treatment with 8 weeks of G/E 
100/50mg daily was initiated no later than 6 months after infection with an HCV genotype 
1 or 4. The primary endpoint was sustained virological response (SVR) in all patients who 
started treatment. The 93% SVR observed in the phase III study of 12 weeks of G/E 
for chronic HCV was used as comparator with a 10% non-inferiority margin. Here we 
present the final results of the study.  
  
Findings and interpretation 
From 02/2016 to 03/2018, 146 patients were diagnosed with a recently acquired HCV 
infection, 86 were included and 80 started therapy. 79 had an SVR (99%; 95% C.I.93-100%, 
non-inferiority proven). Also, all 14 patients who were infected with a virus carrying a 
clinically significant polymorphism in NS5a were cured. If reinfections were considered 
treatment failures, the SVR was 94% (95%C.I. 86-98%). No related serious adverse events 
were seen and none of the adverse events led to study drug discontinuation. The most 
common adverse event was a new sexually transmitted infection (19; 24%). Eight weeks of 
G/E cured 99% of the acute HCV infections. Therefore, 8 weeks of G/E can be regarded as 
an effective treatment for acute HCV infection genotype 1 and 4.  
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Introduction           
 
In 2016 the World Health organization released a global health sector strategy on viral 
hepatitis. One of these goals was combating hepatitis C, towards its elimination as a public 
health threat, and consisted of a 90% reduction in new HCV infections (incidence) and a 
65% reduction of HCV-related deaths (mortality)1.  
 
With the advent of direct acting antivirals (DAA), this goal seems to come closer in some 
well-defined populations with a high HCV prevalence such as HIV-positive men who have 
sex with men (MSM)2. However, they are also one of the patient populations with the 
highest incidence of acute HCV infections and HCV reinfections3,4. Although compared to 
people who inject drugs, HIV positive MSM represent an intermediate prevalence and 
incidence group (1-1.5/100 patient years of follow-up), a subgroup with extremely risky 
behaviour and therefore a much higher incidence exists. Recent modelling studies as well 
as observational studies suggest that, as a result of the DAA-treatment as prevention effect, 
a systematic and nationwide treatment of chronic HCV in HIV-infected MSM could lead to a 
substantial decrease in the HCV prevalence as well as incidence of new HCV infections2,5-8.  
 
However, additional interventions are also needed if HCV elimination is to be achieved9. 
Indeed, as long as large and conclusive studies on the effectivity of DAA for acute HCV are 
lacking, treatment during the acute phase of the infection is often not possible due to 
registration and/or reimbursement restrictions. Therefore, treatment of the acute infection 
has to be postponed until the chronic phase. This delayed treatment approach may not 
only be unsatisfactory from the individual patient perspective, but also from a public health 
perspective, as overall healthcare costs are likely to increase due to ongoing HCV 
transmissions caused by this treatment delay. Indeed, modelling studies demonstrated a 
benefit in costs when treatment was initiated in the acute phase of the infection in patients 
with the risk of transmitting HCV to others10. If HCV could be effectively treated in the 
acute phase of infection among high risk patients like in HIV positive MSM, this could aid 
micro-elimination of HCV from this subgroup in an attempt to reach global elimination of 
HCV according to the WHO elimination goals11. 
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For patients with chronic HCV of the genotype 1b, 8 weeks of grazoprevir/elbasvir was 
shown to be very effective in for patients with F0-F2 with 79/81 having an SVR12 in the 
STREAGER trial and a similar study is ongoing for genotype 4 infected patients12,13. However 
with an SVR of 80% (95% CI 61-92), 8 weeks of grazoprevir/elbasvir led to less favorable 
results for patients with a chronic infection of the genotype 1a in a phase II study14.  
 
In the interferon era, the treatment of HCV was much more effective when given during 
the first 6 to 12 months after infection even when the treatment duration was shortened 
substantially15-17. The few studies that have examined the efficacy of interferon-free DAA 
therapy during the acute phase of an HCV infection only included a small number of 
patients (n=20 to 30) and almost exclusively with a genotype 1 infection. The observed cure 
rates varied between 77-100%, but the studies were too small to draw any definite 
conclusions and were recently reviewed by Martinello et al.18.  
 
The Dutch Acute HCV in HIV study no. 2 (DAHHS2) evaluated the efficacy and safety of 
grazoprevir/elbasvir for eight weeks among people with acute genotype 1 or 4 HCV 
infection. 
 
Methods            
 
Study design and participants  
This investigator-initiated trial was designed as a single-arm, prospective, open-label, 
multicentre phase 3b trial. Adult patients (≥ 18 years) with an acute HCV genotype 1 or 4 
infection were recruited in in the Netherlands and Belgium in 15 hospitals, all of which also 
had an HIV outpatient clinic. All HIV treatment centres in the Netherlands and in the Dutch 
speaking part of Belgium were informed about the trial and invited to refer patients to one 
of the study sites. In all major Dutch cities, the largest HIV treatment centre participated as 
study site. Furthermore, the staff of all other Dutch HIV centres were informed about the 
study and received newsletters with contact information to facilitate referral to one of the 
study sites. Information about the study was posted on several websites. In Belgium the 
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HIV centre with the highest reported incidence of acute HCV was the study site (ITG, 
Antwerp) but all HIV centres could refer patients to Antwerp.  
 
Patients were included if they had an acute HCV genotype 1 or 4 infection that was ≤26 
weeks old according to the presumed day of HCV infection. An acute HCV infection was 
defined as a positive anti-HCV IgG or positive HCV RNA in the presence of a documented 
negative HCV antibody or HCV RNA test in the previous 12 months. If no documented 
negative test in the last 12 months was present, patients were also eligible but only if they 
fulfilled all of the following criteria: 1) a positive HCV RNA in association with an acute rise 
in ALAT >5 time the upper limit of normal with a documented normal ALAT in the previous 
12 months; 2) no recent introduction of any other medication that may explain the ALAT 
elevation; 3) documented negative HCV IgG antibody test at any time in the past; and 4) no 
other explanation for ALAT elevation (e.g. Hepatitis A or E or CMV or new co-medication)19.  
 
The presumed day of HCV infection was calculated as the midpoint between the most 
recent date without any laboratory signs of an HCV infection (negative HCV test and/or 
normal ALAT) and the date of the first positive HCV test. Therapy was initiated no later than 
26 weeks after the calculated day of HCV infection. Unless their CD4 was >500/μl without 
therapy, HIV infected patients had to be on cART with an HIV-RNA <400 copies/ml at the 
time of screening. Patients with a history of liver cirrhosis of any aetiology or patients with 
an untreated chronic hepatitis B (HBV) infection were excluded as well as patients with a 
virologically controlled HBV who had significant liver fibrosis on transient elastography (F2 
or higher).  
 
Procedures  
All subjects were treated with 8 weeks of grazoprevir/elbasvir 100/50 mg given as an oral 
fixed drug combination tablet once daily. The decision to observe patients for possible 
spontaneous clearance of the HCV infection was left to the treating physician. Patients 
were seen in a HIV clinic at screening, baseline, week 2, 4 and 8 during therapy and 4, 12 
and 24 weeks after therapy. Laboratory results of those visits were reported to the 
investigators by the participating study centres after each study visit.  Adherence was 
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evaluated by pill counts during week 2, week 4 and week 8 of the study. Adverse events 
were collected according to the Common Terminology Criteria for Adverse Events20 by the 
participating study centres and reported to the investigators after each study visit.  
 
Outcomes 
The primary efficacy endpoint was sustained virological response at post-treatment week 
12 (SVR12; HCV RNA <15 IU/ml) in all patients who started treatment. HCV RNA was 
determined with the local standard of care HCV RNA test (TaqMan 2.0 assay (Roche 
Diagnostics) or Abbott Realtime M2000; lower limits of HCV RNA detection resp. 15 and 12 
IU/mL). Because the incidence of HCV reinfection is high in HIV-positive MSM2,21, patients 
with a documented HCV reinfection 12 weeks after the end of therapy were not considered 
to have treatment failure in the primary analysis as predefined in the study protocol. 
Reinfection was defined as the detection of a different virus at SVR12 compared to the 
baseline virus, either by HCV genotype switch or due to the detection of a different HCV 
variant of the same genotype by phylogenetic analysis using a fragment of the envelope E2 
gene which includes the hypervariable region 122. Subsequently, patients who were HCV 
RNA positive at SVR12 and in whom the same virus as at baseline was detected, were 
considered as treatment failure. Sequences were analysed in the context of local HCV 
MSM-variants22. Secondary endpoints were safety, SVR12 in in genotype 1 and in genotype 
4 infections separately and SVR12 in all patients who started treatment in which patients 
lost to follow-up or who discontinued treatment for other reasons than virological failure 
were excluded. 
 
Sequencing and alignment method 
The genotype and the subtype of the sequences was first assessed using the Rega HCV 
genotyping tool23. Sequences classified with a particular genotype were then aligned to a 
reference sequence with the same genotype and trimmed to equal length. NS5A 
resistance-associated substitutions (RAS) were defined as all changes in amino acids in the 
positions 28, 30, 31, 58 and 93. In addition, at position 58 only the 58D RAS was considered 
relevant.  
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Statistical analysis 
With a sample size of 80 patients and a non-inferiority margin of 10% the study would have 
89% power to detect non-inferiority compared to a SVR rate of 93% observed in patients 
treated with 12 weeks of grazoprevir/elbasvir for chronic HCV of the genotype 1a or 4 in 
the phase 3 C-EDGE study24. Data were analysed using IBM SPSS statistics® v21. For the 
primary as well as the secondary endpoints, the proportion of patients with SVR12 was 
calculated with exact 2-sided Clopper-Pearson confidence intervals (C.I.) and non-inferiority 
was concluded if the lower 95% C.I. of the SVR12 was above 83%.  
 
Ethical statement 
The institutional review board of all participating centres as well as the competent 
authority of both countries approved the study and the study was performed in accordance 
with GCP standards. All subjects gave written informed consent. The protocol was 
registered at ClinicalTrials.gov (NCT02600325).  
 
Role of the funding source 
This investigator-initiated study was supported by a research grant to BJAR from MSD and 
Health-Holland. MSD also provided the study drugs. The funding sources had no role in 
study design, no role in the collection, analysis, or interpretation of the data and no role in 
the writing of the report. The corresponding author and the last author both had full access 
to all of the data and the final responsibility to submit for publication. 
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Results            
 
Participants and baseline characteristics 
Patients were recruited between February 15th, 2016, and March 2nd, 2018. In total, 146 
patients with a recently acquired HCV were evaluated for eligibility of whom 86 were 
enrolled and 80 started therapy. Reasons for non-eligibility and not starting therapy can be 
found in figure 1. All patients completed the treatment period and no patients were lost to 
follow up. A negative HCV RNA or antibody test on plasma that had been collected and 
stored at the preceding HIV outpatient visit (typically 6 months earlier) led to the acute HCV 
diagnosis in the majority of the patients (n=72) while 8 patients fulfilled the alternative 
definition. Their mean age was 47 years and all patients were MSM and 90% were 
Caucasian (table 1).  In 24% of the patients the current HCV episode was a reinfection, 64% 
of all patients had an HCV genotype 1a infection and 36% a genotype 4. The median 
baseline ALT was 139 IU/ml (IQR 74-315) and the median baseline HCV RNA was 310,000 
IU/ml (IQR 34000-1,400,000). 91% of the patients were HIV-coinfected and all were on 
cART, with an HIV viral load <50 copies/ml in 98% of co-infected patients and a median CD4 
cell count of 605/μl (IQR 490-765). Regarding the HIV-negative patients, 4 out of 7 were 
receiving PrEP. No HBV-coinfected patients were included. Only 2 out of the 80 patients 
had a symptomatic (icteric) acute hepatitis C at screening. The mean total bilirubin was 13 
+-6 μmol/L and only 13 out of 80 patients had a total bilirubin above the upper limit of 
normal (ULN > 17 μmmol/L; max. 39 μmol/L). 
 
Virological response 
Among the 80 patients that were enrolled and started treatment, 75 (94%) were HCV RNA 
negative 12 weeks after the end of therapy. No patients were lost to follow up or 
interrupted treatment. Of the 5 patients that were HCV RNA positive at that time, the 
phylogenetic analysis showed that 1 patient had failed treatment while the other 4 had a 
reinfection with a different HCV strain (figure 2, end of chapter). Therefore, the primary 
endpoint was observed in 79 of the 80 patients (99%; 95% C.I, 93-100%) and this was non-
inferior to the pre-defined 93% success rate. Even if the 4 HCV reinfections were 
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considered treatment failures, a non-inferior HCV cure rate of 94% (95% C.I. 86-98%) was 
observed. In the 4 cases of reinfection, HCV RNA was <15 IU/ml at the end of therapy. 
Therefore, it is likely that the reinfection occurred between week 8 and week 20 of the 
study. The genotype that was detected at the time of reinfection was genotype 1a in 3 and 
genotype 4 in 1 patient. The patient, in whom treatment had failed, was a 50-year-old male 
with a well-controlled HIV-coinfection and a genotype 4d HCV infection with a baseline viral 
load of 14,700,000 IU/ml. Although his HCV RNA load declined rapidly during therapy HCV 
RNA remained detectable at his last day of therapy (17 IU/ml). No NS3 or NS5A resistance 
associated variants were detected in the HCV viruses sequenced at baseline and at SVR12 
time point in this patient. According to the patient and confirmed by drug accountability 
records treatment adherence had been perfect. Response rates were comparable within 
the different patient subgroups of HCV genotype 1 versus 4 (p=0.4) or HIV-positive versus 
negative patients (p=1.0) (table 2, figure 3). Furthermore, the impact of the baseline HCV 
viral load on SVR12 was evaluated and showed that all but one of the 23 patients with a 
baseline viral load above 1 million IU/mL had an SVR (figure 4). 
 
 
 
 
 
Figure 1. Flow diagram. 
AE: adverse event. cART: combined 
antiretroviral therapy. 
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Table 1. Baseline demographic characteristics and characteristics of disease.  
*Mean (+-SD), †Median (IQR) 
 
 
 All patients Genotype 1a Genotype 4 
Number 80 51 29 
Age – years *   47 (+-10) 47 (+-10) 49 (+-8) 
Male sex – no. (%) 80 (100) 51 (100) 29 (100) 
Caucasian – no. (%) 72 (90) 46 (90) 26 (90) 
Transmission route HCV – no. (%)    
          MSM 80 (100) 51 (100) 29 (100) 
Current episode is a reinfection – no (%) 19 (24) 12 (24) 7 (24) 
How many HCV episodes?    
          1 61 (76) 39 (76) 22 (76) 
          2 15 (19) 9 (18) 6 (21) 
          3 or more 2 (5) 3 (6) 1 (3) 
ALT – IU/ml † 139 (74-315) 144 (76-310) 136 (70-427) 
HCV RNA – IU/ml †  310,000  
(34,000-1,400,000) 
 330,000 
(31,000 – 1,400,000) 
  250,000  
  (49,000 – 1,500,000) 
Time between estimated infection date and 
HCV treatment - months * 
4.4 (+-1.2) 4.3 (+-1.1) 4.6 (+-1.3) 
Time between first positive HCV RNA test and 
HCV treatment – months * 
2.0 (+- 1.0) 2.0 (+- 1.0) 2.0 (+-1.1) 
HBV coinfection – no. (%) 0 0 0 
HIV coinfection – no. (%) 73 (91) 46 (90) 27 (93) 
          CD4 cell count - /μl † 605 (490-765) 601 (497-770) 610 (396-767) 
          HIV viral load <50 copies/ml – no. (%) 71 (98) 45 (98) 26 (96) 
          Patient on cART – no. (%) 73 (100) 46 (100) 27 (100) 
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Baseline NS5A resistance-associated substitutions (RAS) 
Of the subgroup of patients infected with HCV genotype 1a (n=51), 12 patients had a M28V 
substitution, of which 1 patient showed two substitutions (M28V + Y39H). One patient had 
a single Q30R substitution and another patient had a single Y93H substitution (figure 5). All 
these 14 patients reached SVR12. In the subgroup of patients infected with HCV genotype 4 
(n=29) no NS5A RAS were found. The baseline viral load in patients with an NS5a mutation 
was 366,500 IU/ml (IQR 70,925-1,039,250 IU/ml) and comparable to the viral load in the 
other patients (308,944 IU/ml; IQR 45,200-1,380,000). Also, the time from diagnosis to 
treatment initiation was comparable (4.4+-1.0 and 4.4+-1.2 months respectively). 
 
 
Table 2. Treatment outcomes, overall and according to genotype and HIV-status.  
 All patients Genotype Hiv-status 
 A 
Reinfection  
not counted 
as treatment  
failure 
B 
Reinfection  
counted as  
treatment 
failure 
C(*) 
 
1a 
D(*) 
 
4 
E(*) 
 
Positive 
F(*) 
 
Negative 
 
Started therapy – no.  
 
80  
 
80  
 
51 
 
29 
 
73 
 
7 
Primary endpoint – no. 80 80 51  29 73 7 
        SVR12 – no. 75 75 49 26 68 7 
        Reinfection – no.  4 4 2 2 4 0 
        Treatment failure– no. 1 1 0 1 1 0 
 
Total cured – no.  
 
79/80 
 
75/80 
 
51/51 
 
28/29 
 
72/73 
 
7/7  
        % (95% exact CI) 99% (93-100) 94% (86-98) 100% (93-100) 97% (82-100) 99% (93-100) 100% (59-100) 
 
A: all patients (n=80), reinfection is not counted as therapy failure (primary endpoint). B: all patients 
(n=80), reinfection is counted as failure. C: patients with genotype 1a infection (n=51). D: patients with 
genotype 4 infection (n=29). E: HIV positive patients (n=73). F: HIV negative patients (n=7). CI: 
confidence interval. (*) In group C, D, E and F reinfections are not counted as treatment failure.   
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Drug-drug interactions between the study regime and cART 
At screening, 27 of the 28 patients on a HIV regimen susceptible to drug-drug interactions 
with grazoprevir/elbasvir were successfully switched to a compatible cART regimen. This 
included 8 patients on elvitegravir/cobicistat, 8 on efavirenz, 6 on nevirapine and 5 on 
darunavir/ritonavir. 
 
 
Figure 3. Treatment outcome in relation to the non-inferiority margin of 10%. 
 
A: all patients (n=80), reinfection not counted as therapy failure (primary endpoint). B: all patients 
(n=80), reinfection counted as failure. C: patients with genotype 1a infection (n=51). D: patients with 
genotype 4 infection (n=29). E: HIV positive patients (n=73). F: HIV negative patients (n=7).  
 
 
Figure 4. Baseline HCV viral load (IU/ml) according to treatment outcome. 
 
 
Black: sustained virological response 12 weeks after therapy. Grey: reinfection. White: treatment failure.  
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Adherence and safety 
Based on pill-count, the adherence during the 8 weeks of treatment was 95%. The few 
patients that had not finished the 56 pills at the end of week 8 took the remaining pills in 
week 9. The study regimen was generally well tolerated; 59 of 80 patients (74%; 95% C.I. 
63-82%) reported at least one adverse event (table 3b) of which 66% were considered mild 
in severity by the investigator. No related serious adverse events were seen and none of 
the adverse events led to study drug discontinuation (table 3a). The most common adverse 
event was a new sexually transmitted infection (STI), 20 different STI’s were seen in 19 
patients (24%). One patient was diagnosed with both Chlamydia trachomatis and syphilis 
during the study, 6 patients were newly diagnosed with syphilis, 4 with Chlamydia 
trachomatis, 3 with gonorrhoea, 2 with Lymphogranuloma venereum, 1 with scabies, 1 
with Shigella dysentery and 1 with sexually transmitted hepatitis A. The most common 
reported possibly related adverse events were fatigue (11 patients; 14%), headache (7; 
9%), insomnia (7; 9%), mood changes (5; 6%), dyspepsia (5; 6%), concentration impairment 
(4; 5%) and dizziness (4; 5%). Of note, one patient was screened but eventually did not 
initiate study medication because he had a (non-serious) adverse event after a switch in the 
cART regimen, as his prior cART regimen was incompatible with grazoprevir/elbasvir.  
 
 
Figure 5. Proportion of NS5A RAS in patients infected with HCV genotype 1a. 
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Table 3a. Mortality, serious adverse events and any adverse events 
 
 All patients (n=80) 
Death – no. (%) 0 
Serious adverse event – no. (%)  
          Traumatic rectal bleeding – no. (%) 1 (1) 
          Low back surgery – no (%) 1 (1) 
Any adverse event – no. (%) 59 (74) 
 
 
Table 3b. Most common adverse events 
 
 All patients (n=80) 
Sexual transmittable infection – no. (%) 19* (24) 
Upper respiratory infection – no. (%) 15 (19) 
Fatigue – no. (%) 14 (18) 
Infections – no. (%) 11 (14) 
Diarrhoea – no. (%) 9 (11) 
Insomnia – no. (%) 9 (11) 
Mood changes – mo. (%) 8 (10) 
Dyspepsia– no. (%) 8 (10) 
Skin disorder – no. (%) 8 (10) 
Headache – no (%) 7 (9) 
Dizziness – no. (%) 5 (6) 
Injury – no. (%) 4 (5) 
Concentration impairment – no. (%) 4 (5) 
Back pain – no. (%) 4 (5) 
*20 Sexual transmittable infections in 19 patients.  
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Discussion and conclusion         
 
In the largest study on the treatment of acute HCV with DAA to date, an 8-week course of 
grazoprevir and elbasvir cured 79 of the 80 (99%) patients diagnosed with an acute HCV of 
the genotypes 1a or 4. Its non-inferiority to the SVR observed for chronically infected 
patients treated with 12 weeks of grazoprevir and elbasvir in the phase III C-EDGE trial, 
convincingly demonstrates that this regimen is also effective during the acute phase of an 
HCV infection. Furthermore, this high cure rate was achieved using a shorter treatment 
duration. The treatment was very well tolerated and overall compliance was excellent. In 
contrast to previous studies on DAA therapy for acute HCV25-29, the sample size of our study 
was sufficiently large to draw statistical conclusions about non-inferiority and our study 
also included a substantial number of HCV genotype 4 infections. Indeed, despite the fact 
that a substantial number of acute HCV infections among MSM in Europe are of the 
genotype 4, previous studies on DAA for acute HCV infection were almost entirely limited 
to genotype 1a.  
 
Specific to the DAA regimen we studied, the grazoprevir/elbasvir label in the USA indicates 
that testing for NS5a polymorphisms should be pursued and treatment should be extended 
from 12 to 16 weeks in patients with chronic HCV genotype 1a infection with certain NS5a 
polymorphisms. As the relevance of NS5a polymorphisms in patients treated for an acute 
HCV has never been demonstrated we used a fixed 8-week treatment duration for all 
patients and did not test for NS5a polymorphisms before treatment initiation. All 14 
patients infected with a genotype 1a that carried an NS5a polymorphism had an SVR12 
after 8 weeks of therapy. This is in sharp contrast with the response rate of 70% (39/56) 
described in patients with a chronic genotype 1a infection treated for 12 weeks (p=0.02) if 
the virus carried baseline NS5A polymorphisms that led to a change of the amino acids at 
positions 28, 30, 31 and 9330. Also, we did not observe any difference in the HCV RNA 
kinetics during treatment of the patients with and without NS5a polymorphisms (data not 
shown). Therefore, our data suggest that extending the treatment duration for patients 
with an acute genotype 1a infection in the presence of baseline NS5a polymorphisms is 
unnecessary. 
the DAHHS 2 study 
61 
 
3 
For HIV-coinfected patients, some of the antiretroviral drugs cannot be combined with 
grazoprevir/elbasvir (e.g. efavirenz or HIV-protease inhibitors) and this may limit its use in 
HIV positive patients. However, 27 of the 28 patients on a HIV regimen susceptible to drug-
drug interactions with grazoprevir/elbasvir at the time of screening for this study were 
successfully switched to a compatible cART regimen. These interactions are mainly caused 
by the HCV protease inhibitor grazoprevir. The same interactions are observed with the 2 
most recently FDA and EMA approved DAA regimens as they also both include an HCV 
protease inhibitor (glecaprevir as part of Maviret® and voxilaprevir as part of Vosevi®). 
Furthermore, the fact that 8 weeks of grazoprevir/elbasvir is by far the least expensive of all 
DAA regimens currently available is in favor of this regimen.  
 
While peg-interferon was registered for the treatment of acute HCV when the study was 
designed in 2016, it is no longer used for this indication due to its numerous side-effects as 
well as the availability of DAA therapy for chronic HCV. Also, the SVR observed in a large 
phase III study on 12 weeks of grazoprevir/elbasvir for chronic HCV was available as a 
comparator. Therefore, we used the SVR of 93% observed in this study for patients infected 
with genotype 1a and 4 combined as the comparator24. Given the short interval between 
the HCV diagnosis and therapy initiation in our study of only 2 months, one may argue that 
a compulsory “wait for spontaneous cure” period of 2-3 months may have been preferred 
because it could avoid unnecessary DAA therapy. However, as DAA therapy is very well 
tolerated and the chances of spontaneous cure of HCV in HIV infected patients are small31, 
we considered the DAA treatment as prevention effect of immediate therapy more 
important than avoiding unnecessary DAA therapy. Therefore, the decision to wait for 
spontaneous clearance was left to the treating physician. In general, physicians in the 
Netherlands repeat the HCV RNA measurement 4 weeks after an acute HCV diagnosis to 
evaluate HCV clearance before treatment is initiated. However, this was not defined in the 
protocol and indeed, 14 patients started therapy within 4 weeks after diagnosis. A recent 
modelling study that took the continued risk of onward HCV transmission to sex partners 
into account, showed that treating patients in the acute phase of HCV with a shorter 
regimen is likely to be cost-saving compared with a “wait for spontaneous cure” 
approach10. Given the fact that spontaneous clearance of HCV infections is observed less 
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frequently in HIV infected patients this is even more relevant for patients with HIV21,32. A 
comprehensive review on HCV elimination is available elsewhere9.  
Looking at the presence of possible predictors for spontaneous clearance in our study 
population, only 2 out of the 80 patients had a symptomatic (icteric) acute hepatitis C at 
screening and 13 out of 80 patients had a total bilirubin above the upper limit of normal. 
Combined with the relatively low ALT level at baseline, this illustrates that spontaneous 
clearance was unlikely in our study population. We did not look at IL28B genotypes in our 
cohort. However, in an earlier clinical trial in HIV-positive MSM in the Netherlands in 2013-
2014, 25 out of 55 patients harboured the more favourable CC-genotype15. Whether a 
previous HCV infection and in particular a spontaneously cleared previous infection is an 
indicator of partial protective immune memory or a predictor for spontaneous clearance of 
a new HCV infection remains a controversial issue33. In our population, only 2 of the 19 
patients with an earlier HCV infection in their medical history were cured without HCV 
therapy which illustrates the rarity of spontaneous HCV clearance in HIV positive patients.     
 
Our study has its limitations. We included a uniform study population that mostly consisted 
of Caucasian MSM with an HCV genotype 1a or 4 and used stringent acute HCV diagnostic 
criteria. This acute HCV population truly represents the patient population in which acute 
HCV infections are diagnosed in many European countries and in particular in the 
Netherlands and Belgium2,5. So while this may be a limitation regarding the extrapolation of 
the results to certain regions of the world it is not a limitation in the setting were the study 
was performed. Indeed, HCV transmission via injecting drug use has become rare in both 
countries as a result of harm-reduction interventions like needle exchange programs and 
opioid substitution34. And although the baseline HCV load of our population was lower than 
the typical HCV load in patients with chronic HCV, this is representative of patients with 
acute HCV infection.  
 
The non-pan genotypic nature of grazoprevir and elbasvir combination may be seen as a 
limitation in particular in a setting where the genotyping is not possible or may lead to 
patients getting lost to follow-up before treatment can be initiated. In the setting where 
the study was performed this was not a limitation  as only 6 of the 146 patients evaluated 
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for eligibility had a non-1 non-4 HCV genotype. Therefore, the HCV treatment spectrum of 
grazoprevir/elbasvir was appropriate for 96% of the patients diagnosed with an acute HCV 
in this setting. Furthermore, we did not collect any data on risk behaviour. Finally, the 
absence of a randomized control group could be seen as a limitation as well as we used a 
historical comparator composed of population with chronic HCV infection instead of acute 
HCV infection. However, the 99% cure rate does not leave much room for doubt about the 
efficacy of grazoprevir/elbasvir for the treatment of acute HCV.   
 
Although, to our knowledge, we are the first to report on the non-inferiority for the 
treatment of acute hepatitis C infection with 8 weeks of G/E compared to 12 weeks of G/E 
for chronic hepatitis C infection, other clinical trials on DAA’s for acute hepatitis C are 
currently ongoing. However, as far as we know only the REACT study (NCT02625909) will 
be an adequately powered non-inferiority study of a shorter (6 weeks) compared to the 
standard (12 weeks) treatment duration. Nevertheless, at this moment off-label use of 
early DAA therapy for acute HCV in patients that may transmit HCV to others is already 
advocated by the 2017 European AIDS Clinical Society guideline in order to prevent onward 
transmission35. The 4 HCV reinfections and 20 (other) sexually transmitted diseases 
diagnosed during 20 weeks of follow-up in our study clearly illustrate the continued risk 
behaviour and therefore risk for ongoing transmission after HCV diagnosis. Together with 
the observation that 24% of the patients in our study already had a history of HCV 
infection, this shows that not only immediate DAA therapy should be implemented on the 
short term but also (research on) behavioural interventions in MSM diagnosed with an 
acute HCV are badly needed to reduce the risk of both HCV reinfections and onward HCV 
transmission and enhance the possibility of micro-elimination of HCV in MSM.  
 
In conclusion, a short 8-week grazoprevir/elbasvir regimen was highly effective for the 
treatment of an acute HCV genotype 1 or 4 infection. 
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Figure 2. Evolutionary relationships of taxa, phylogenetic analysis of patients who were HCV RNA 
positive 12 weeks after the end of treatment. 
Phylogenetic trees of  local genotype 4 (A) and genotype 1a (B) HCV sequences obtained from MSM36. 
Sequences of patients from this study with detectable HCV RNA 12 weeks after the end of therapy are 
represented by a unique colour. The tree represents the genetic distance between variants. Except for one 
patient, the large genetic distance for the 4 other patients shows that these patients all became reinfected 
with a new virus before SVR12.  Sequence labels indicate the sampling date. The evolutionary history was 
inferred using the Neighbor-Joining method37. The optimal tree with the sum of branch length = 3.39563938 
is shown. The percentage of replicate trees in which the associated taxa clustered together in the bootstrap 
test (1000 replicates) are shown next to the branches38. The tree is drawn to scale, with branch lengths in the 
same units as those of the evolutionary distances used to infer the phylogenetic tree. The evolutionary 
distances were computed using the Maximum Composite Likelihood method39 and are in the units of the 
number of base substitutions per site. The analysis involved 137 nucleotide sequences. Codon positions 
included were 1st+2nd+3rd+Noncoding. All ambiguous positions were removed for each sequence pair. There 
were a total of 525 positions in the final dataset. Evolutionary analyses were conducted in MEGA640. 
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Abstract            
 
Background 
The Netherlands has provided unrestricted access to direct-acting antivirals (DAAs) since 
November 2015. We analyzed the nationwide HCV treatment uptake among HIV/HCV-
coinfected patients. 
Methods 
Data were obtained from the ATHENA HIV observational cohort in which >98% of HIV-
infected patients ever registered since 1998 are included. Patients were included if they 
ever had 1 positive HCV RNA, did not spontaneously clear and were known to still be in 
care. Treatment uptake and outcome were assessed. When patients were treated more 
than once, only data of the most recent treatment episode were included. Data were 
updated until February 2017. In addition, each treatment center was queried in April 2017 
for a data update on DAA treatment and achieved SVR. 
Results 
Of 23,574 HIV-infected patients ever linked to care, 1471 HCV-coinfected patients (69% 
men who have sex with men (MSM), 15% people who (formerly) inject drugs and 15% 
another HIV transmission route) fulfilled the inclusion criteria. Eighty-seven percent 
(1284/1471) had ever initiated HCV treatment between 2000 and 2017, 76% (1124/1471) 
were cured and in 6% (92/1471) DAA treatment results were pending. Among MSM 83% 
(844/1022) were cured and in 6% (66/1022) DAA treatment results were pending. Overall 
187 patients had never initiated treatment, 14 patients failed DAAs and 54 patients failed a 
pegylated-interferon-alpha based regimen. 
Conclusion 
Fifteen months after unrestricted DAA availability the majority of HIV/HCV-coinfected 
patients in the Netherlands are cured (76%) or awaiting DAA treatment results (6%). This 
rapid treatment scale-up may contribute to future HCV elimination among these patients.  
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Introduction           
 
Treatment with combinations of direct-acting antivirals (DAAs) is short, safe and highly 
effective in curing chronic hepatitis C virus (HCV) infection1. However, its high costs has led 
to restricted reimbursement in many countries. In the Netherlands, the first all-oral DAA 
regimens became available for chronic hepatitis C in June 2014, but initially only for 
patients with severe liver fibrosis defined as liver fibrosis stage F3 or higher. These fibrosis 
restrictions also applied to human immunodeficiency (HIV)-infected patients. 
 
On the first of November 2015, the Dutch government among other countries in the world 
expanded the reimbursement criteria and made DAA treatment possible for all patients 
with chronic HCV, regardless of their fibrosis stage. Scaling up HCV treatment is one of the 
interventions which, combined with increased harm reduction strategies and scaling up of 
testing may lead to a lower HCV incidence and prevalence and eventually to HCV 
elimination2,3.  
 
Here we describe the national HCV treatment uptake in HIV/HCV-coinfected patients in the 
Netherlands using data from the AIDS Therapy Evaluation in the Netherlands (ATHENA) HIV 
observational cohort. This cohort captures data on over 98% of patients with HIV and in 
care in the Netherlands and is therefore highly representative of the overall Dutch HIV/HCV 
epidemic.  
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Methods            
 
ATHENA cohort  
HIV-care in the Netherlands is provided by 26 designated treatment centers. As an integral 
part of HIV care, the HIV Monitoring Foundation (Stichting HIV Monitoring) is responsible 
for prospectively collecting demographic data, relevant HIV and treatment data, as well as 
data on comorbidities including viral hepatitis coinfection, from HIV-infected people living 
in the Netherlands and receiving care in one of these treatment centers. In addition, 
residual plasma from HIV viral load assays is stored in each center. This data collection is 
known as the ATHENA cohort 4. The ATHENA cohort was initiated in 1998 and captures data 
from over 98% of all patients diagnosed with HIV and in care in the Netherlands. Data 
collection is still ongoing and the database of the ATHENA cohort is locked and updated 
twice a year. This paper includes the data from the February 2017 database lock, which is 
15 months following unrestricted access to DAAs in the Netherlands. Furthermore, on April 
15th 2017 each center was queried about their HCV infected patients whose treatment 
status was uncertain, and/or whose sustained virological response (SVR) status had been 
pending in February 2017, in order to render data as up-to-date as possible. 
 
Included patients and variables of interest 
A patient was considered to be linked to care if he or she had visited one of the 26 HIV 
clinics at least once and had not opted-out to be included in the ATHENA cohort. Patients 
were included in the present analysis if they had at least one positive HCV RNA test and had 
not spontaneously cleared their HCV (HIV/HCV-coinfected patients defined as ‘linked to 
care’). Spontaneous clearance was defined as a negative HCV RNA test following a positive 
HCV RNA test without initiation of HCV treatment. To label the HIV/HCV-coinfected 
patients who were ‘retained in care’ on February 1th 2017, patients were excluded if they 
had died, moved abroad or were lost to follow-up. Lost to follow-up was defined as the 
absence of a clinical visit after January 1st 2016. Included patients were assessed for age, 
gender, country of origin, HIV transmission route, last known CD4 cell count and HIV-1 RNA, 
the usage of combination antiretroviral therapy (cART), the presence of severe liver 
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fibrosis, the usage of any HCV treatment and the outcome of their last HCV treatment. HIV 
transmission route was used as a proxy for HCV transmission route. Severe liver fibrosis was 
defined as liver fibrosis stage Metavir F3 or higher by either liver biopsy or transient 
elastography result (≥9.5 kPa), based on the most recent available biopsy or transient 
elastography result. SVR was defined as a negative HCV RNA test at least 24 weeks after the 
end of HCV treatment with a pegylated interferon-alpha based regimen (SVR24) or as a 
negative HCV RNA test at least 12 weeks after the end of HCV treatment with DAAs 
(SVR12). 
 
HCV treatment cascade  
Treatment uptake and outcome were assessed using a treatment cascade. In this cascade 
every patient was depicted only once based on the most recent treatment the patient had 
received. For example, if a patient was first treated unsuccessfully with a pegylated 
interferon-alpha based regimen and subsequently with DAAs resulting in a SVR12, only the 
last treatment was accounted for in this cascade. First, the proportion of patients who had 
received treatment was calculated. Second, the proportion of patients who had completed 
any treatment was calculated. Last, the proportion of patients who reached SVR was 
calculated. For every step in the cascade, also the ‘gap’ was described (respectively the 
untreated patients, patients with ongoing treatment or awaiting SVR12 results and 
unsuccessfully treated patients).  
 
Ethics statement and statistics  
At its inception, the ATHENA cohort was approved by the institutional review board of all 
participating centers. Individuals can opt out after being informed by their treating 
physician of the purpose of data and sample collection. Data are pseudonymised and made 
available to investigators in a coded form. Coded data may be used for scientific purposes 
without further consent. For the purpose of our analysis, only existing data have been used 
and therefore no additional review or consent has been necessary. Chi square was used to 
compare categorical variables. P-values of ≤ 0.05 were considered statistically significant. 
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Results            
 
Number of HIV/HCV-coinfected patients 
Of 23,574 HIV patients ever registered as having been linked to care on the 1st of February 
2017, 2503 had at least one positive HCV RNA test. After exclusion of patients who had 
spontaneously cleared their HCV (n=514), 1989 HIV/HCV-coinfected patients who had ever 
been linked to care remained. Of these 1989 patients, 321 patients had died (of whom 42 
had a confirmed liver-related death), 83 patients had moved abroad and 114 patients were 
lost to follow-up (median duration of being lost to care 5 years (interquartile range (IQR) 2-
11 years), resulting in 1471 coinfected patients who were still retained in care in February 
2017 (figure 1), and who were included in the current analysis. Of these HIV/HCV-
coinfected patients retained in care 90% were male (1325/1471) and 67% were born in the 
Netherlands (983/1471, table 1). The most commonly reported HIV transmission route was 
MSM (69%; 1022/1471), followed by a history of injecting drug use (15%; 224/1471). For 
the remaining 15% (225/1471) HIV transmission had occurred through another route or 
was unknown. HCV genotype 1 was the most prevalent (61%; 896/1471), followed by HCV 
genotype 4 and 3 (18% and 9%, respectively). Seventeen percent (244/1471) had liver 
fibrosis stage F3 or higher. 
 
Treatment uptake and outcome  
Of the included 1471 HIV/HCV-coinfected patients, 1284 had ever initiated HCV treatment 
between 2000 and 2017 (figure 2). Of these, 582 had been treated with an old HCV 
regimen (interferon-alpha, pegylated interferon-alpha +/- ribavirin +/- boceprevir or 
telaprevir), and 702 patients had received or were still receiving a currently used DAA-
regimen (figure 3). Of those treated with DAAs, 259 (37%) were previously treated with 
pegylated interferon-alpha based antiviral regimens. One-hundred eighty-seven patients 
had never initiated any form of HCV treatment and 68 patients had failed prior HCV 
treatment and were still in need of retreatment. Of these 68 patients, 14 patients had 
failed DAAs and the remaining 54 had failed a (pegylated) interferon-alpha based regimen.  
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Table 1  Baseline characteristics of included patients in February 2017 
 
 
Retained in 
care Untreated Ever treated 
SVR 
achieved 
Ongoing 
treatment/ 
awaiting 
SVR 
Treatment 
failure 
Total (n) 1471  187 1284 1124 92 68 
Median age at 1 Feb 2017 
(IQR) 
50 (44-56)  51 (43-57)  50 (44-56)  50 (44-56)  49 (42-55)  49 (46-55) 
Gender (n) 
Male  
Female  
 
1325 
146 
 
150 
37 
 
1175 
109 
 
1027 
97 
 
86 
6 
 
62 
6 
Region of origin (n) 
Netherlands  
Western Europe 
Sub Saharan Africa 
Caribbean/Latin America 
Other 
 
983 
161 
35 
99 
193 
 
102 
22 
5 
20 
38 
 
881 
139 
30 
79 
155 
 
775 
126 
28 
69 
126 
 
61 
9 
0 
5 
17 
 
45 
4 
2 
5 
12 
HIV transmission route (n) 
MSM 
(former) PWID 
Heterosexual contact 
Other/unknown 
 
1022 
224 
127 
98 
 
72 
65 
35 
15 
 
950 
159 
92 
83 
 
844 
127 
81 
72 
 
66 
18 
2 
6 
 
40 
14 
9 
5 
Ever used cART (n) 1454 179 1275 1118 91 66 
cART regimens at HCV 
treatment initiation 
  2 NRTI+ INI 
  2 NRTI+ NNRTI 
  2 NRTI + r/PI 
  Other 
  None 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
 
422 
412 
202 
128 
120 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
 
NA 
NA 
NA 
NA 
NA 
HCV genotype (n) 
1 
  1a 
  1b 
  Subtype not specified 
2 
3 
4 
Other/unknown 
 
896 
676 
94 
126 
69 
131 
258 
117 
 
95 
59 
21 
15 
10 
27 
28 
27 
 
801 
617 
73 
111 
59 
104 
230 
90 
 
 
704 
548 
65 
91 
53 
92 
196 
79 
 
 
53 
40 
6 
7 
5 
6 
19 
9 
 
44 
29 
2 
13 
1 
6 
15 
2 
Liver fibrosis Metavir > F3 
(n) 
244 25  219 192 13 14 
Treatment (n) 
Currently used DAA-regimen 
Older regimen1 
 
NA 
NA 
 
NA 
NA 
 
702 
582 
 
598 
526 
 
90 
2 
 
14 
54 
 
 1 interferon-alpha, pegylated interferon-alpha +/- ribavirin +/- boceprevir or telaprevir 
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Figure 1 Flowchart of included patients 
 
 
Based on their last received treatment, 1124 of the 1192 patients (94%) who were known 
to have completed their HCV treatment reached SVR (figure 2). When restricting the 
analysis to patients who were known to have completed DAA treatment, 98% of patients 
reached SVR12 (598/612). At the time of analysis, overall 76% (1124/1471) of the HIV/HCV-
coinfected patients retained in care had reached SVR and in 6% (92/1471) DAA treatment 
was still ongoing or treatment results were pending. Overall only 255 patients remain to be 
treated. Of the 1284 patients who ever initiated treatment, 743 initiated their last 
treatment in 2014, 2015 or 2016. Shortly following unrestricted access to DAAs, 176, 226 
and 86 patients initiated treatment in the fourth quarter (Q4) of 2015, Q1 2016, and Q2 
2016, respectively, whereas in all other quarters the number of patients who initiated 
treatment was below 50 (figure 4). 
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Antiretroviral treatment during last HCV treatment 
The cART regimens at the time of HCV treatment initiation are listed in table 1. Out of the 
702 patients who were treated with a currently used DAA-regimen, 191 (27%) had switched 
cART regimen in the 3 months prior to HCV treatment initiation. For 130 of those “start of 
HCV treatment” was recorded in the database as reason for the cART switch, for the other 
61 the reason was not explicitly recorded. Of 582 patients who were treated with an old 
HCV treatment regimen, 109 (19%) had switched cART regimen in the 3 months prior to 
HCV treatment initiation. For 54 of those “start of HCV treatment” was recorded in the 
database as reason for the cART switch. 
 
Stratification by liver fibrosis stage F3-F4  
Of the 244 patients classified with liver fibrosis stage F3 or higher and retained in care on 
the 1st of February 2017, 79% (192/244) had achieved SVR while 5% (13/244) were still 
undergoing DAA treatment. Thirty-nine patients with severe liver disease remain to be 
treated (14 patients failed previous treatment and 25 patients were never treated). 
 
 
Figure 2 Treatment cascade of the Dutch HIV/HCV-coinfected population 
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Figure 3A Used DAA regimens in the Dutch HIV/HCV-coinfected population 
 
 
 
 
 
 
Figure 3B Schematic overview of availability of DAAs with regard to liver fibrosis stage over time 
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Stratification by HIV transmission route 
Men who have sex with men (MSM) 
1022 HIV/HCV-coinfected patients identified as being MSM were retained in care as of 
February 1st 2017. SVR was achieved in 83% (844/1022), which was significantly higher 
compared to the 76% with SVR in the overall population (p<0.001). In 6% (66/1022) DAA 
treatment was still ongoing or treatment results were pending. Thus, only 112 MSM remain 
to be treated. 
 
People who (formerly) inject drugs (PWID) 
Of the 224 HIV/HCV-coinfected patients retained in care as of February 1st 2017 and 
classified as (former) PWID, 57% (127/224) reached SVR, which was significantly lower 
compared to the overall population (p<0.001). In 8% (18/224) DAA treatment was still 
ongoing or treatment results were pending. 
 
Characteristics of patients who never initiated treatment 
In the patients who never initiated treatment (n=187) the proportion of women was 
significantly higher compared to the proportion in the patients who ever received 
treatment (n=1284) (20% versus 8%; p<0.001). The proportion of MSM was lower (39% 
versus 74%, p<0.001) and the proportion of (former) PWID was higher (35% versus 12%, 
p<0.001). Four percent of the patients untreated for HCV never received cART, compared 
to 1% in the group treated for HCV (p<0.001).  
Region of origin was significantly different between the two groups (overall p<0.001), with 
a higher proportion of patients from the Netherlands among the treated patients (69% 
versus 55%) and a lower proportion of patients from the Caribbean and Latin America (6% 
versus 11%). Also HCV genotype was significantly different between the two groups (overall 
p<0.001), with a higher proportion of genotype 1 (62% versus 51%) and a lower proportion 
of genotype 3 (8% versus 14%) among the treated patients compared to the untreated 
patients (51% and 14%). Presence of severe liver fibrosis (≥ Metavir score F3) was not 
significantly different between these two groups. 
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Characteristics of patients who failed treatment 
Overall 68 patients failed treatment, of whom 14 failed DAAs and 54 patients failed a 
pegylated interferon-alpha based regimen. Compared to the patients who achieved SVR 
(n=1124), the proportion of (former) PWID was higher in the patients who failed treatment 
(21% versus 11%, p=0.02), and the proportion of MSM was lower (59% versus 75%, 
p=0.003). Furthermore, 3% of the patients who failed HCV treatment never received cART, 
compared to 1% in the group who achieved SVR (p=0.02). Other variables did not differ 
significantly between the two groups.  
 
Of the patients who failed DAAs (n=14), 9 were MSM, 2 were (former) PWID and 3 had 
another HIV transmission route. Seven patients were infected with genotype 1a, 5 patients 
with genotype 4 and 2 patients with another HCV genotype. Three patients had severe liver 
fibrosis (≥ Metavir score F3). 
 
 
 
 
 
Figure 4 HCV treatment uptake per quarter in the years 2014, 2015 and 2016 
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Discussion            
 
As of February 1st 2017 and only 15 months after DAAs were made available to all patients 
with chronic HCV in the Netherlands, 76% of the Dutch HIV/HCV-coinfected patients in care 
had been successfully treated for HCV. Another 6% are still undergoing DAA treatment or 
have completed treatment but are awaiting SVR12. The majority of this 6% can be expected 
to also be cured, as real-world SVR rates after DAA treatment in HIV/HCV-coinfected 
patients are well above 90%5-8. Our results demonstrate that in resource-unconstrained 
settings, a very high treatment uptake is possible in HIV/HCV-coinfected patients within 
only 15 months after unrestricted availability of DAAs. Treatment uptake and HCV cure 
rates were highest in MSM and significantly higher than in other categories of coinfected 
patients. Only 112 HIV/HCV-coinfected MSM remain to be treated. In the Netherlands, in 
contrast to other countries, ongoing HCV transmission occurs mainly among HIV-infected 
MSM9 and transmission among PWID is nearly nonexistent as a result of successful harm 
reduction policies10. Therefore, it is promising that treatment uptake is highest among 
MSM which may favorably contribute to reduce ongoing HCV transmission in the 
Netherlands. However, the fact that treatment uptake in HIV/HCV-coinfected PWID in care 
was significantly lower when compared to the overall population of HIV/HCV-coinfected 
patients is an important signal that might reflect social, medical, psychiatric and/or 
substance-use associated factors or perceived barriers by practitioners as reviewed 
extensively by Grebely et al.11.  
 
Our study has several strengths. The data we analyzed were derived from the longstanding 
ATHENA cohort of HIV-infected patients that also includes data on HCV status and 
treatment. This cohort is representative of all HIV-infected patients in the Netherlands, as it 
captures data from over 98% of all HIV-infected patients in care. Additionally, for this study 
an extra query was performed by contacting each HIV treatment center with a list of HCV 
co-infected patients whose treatment status remained uncertain or whose SVR12 results 
were pending in February 2017. As a result of this query we have made the data of this 
study as up-to-date as possible. To our best knowledge, this is the first study that provides 
truly nationwide data on HCV treatment uptake and cure rates after unrestricted DAA 
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availability for chronic hepatitis C in HIV/HCV-coinfected patients. If this rapid treatment 
scale up is continued, it may contribute to the future elimination of HCV among HIV/HCV-
coinfected patients in the Netherlands. Of note however, additional harm reduction 
strategies and scaling up of HCV testing are likely to be necessary to eventually reach 
elimination2,3. Our study has some limitations. First, only the patients who were retained in 
care could be analyzed and therefore we were unable to provide data on the 114 patients 
who were lost to follow-up. However, these 114 patients represent only 6% (114/1989) of 
the HIV/HCV-coinfected patients overall. Collaboration between different stakeholders 
could possibly lead to (re-)identification of these patients and further elimination of HCV 
from the HIV/HCV-coinfected population. Second, a certain proportion of HCV infections in 
this population will remain undiagnosed as alanine aminotransferase (ALT) levels may 
occasionally remain within normal limits after HCV infection12. However, 99% of HIV-
infected patients currently in care in the Netherlands have been tested for HCV at least 
once4. Third, only the most recent treatment and its outcome was included in the cascade. 
This is an appropriate method to visualize the overall treatment uptake, but in the 
calculation of the SVR rate it may have led to an overestimation, as for patients who failed a 
first treatment with DAAs and were successfully treated a second time, only the second 
result was taken into account in the calculation. Real-world SVR rates found in other studies 
in HIV/HCV-coinfected patients are indeed lower than the 98% that we report5-8. 
Furthermore, due to the cross-sectional design of our analysis HCV reinfections after DAA 
treatment could not be taken into account. As HCV reinfections are common in HIV-
infected MSM13,14, a certain proportion of the population will become reinfected with HCV 
and therefore be again in need of effective treatment. 
 
Although treatment uptake and HCV cure rates are high, the group of patients that remains 
to be treated will be the most challenging. To target this remaining subgroup of HIV/HCV-
coinfected patients, we provided each HIV treatment center with a coded list of patients 
who according to the information available in ATHENA remain in need of curative 
treatment, in order to facilitate the identification and re-evaluation of these patients.  
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In conclusion, we demonstrate a very high treatment uptake among HIV/HCV-coinfected 
patients. Fifteen months after unrestricted availability of DAAs, overall 76% of Dutch 
HIV/HCV-coinfected patients have been cured for HCV and an additional 6% are either still 
being treated with DAAs or awaiting their treatment result. 
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Abstract            
 
Background 
Direct acting antivirals (DAA) cure 95% of patients infected with hepatitis C (HCV). Modeling 
studies predict that universal HCV treatment will lead to a decrease in the incidence of new 
infections but real-life data are lacking. The incidence of HCV among Dutch HIV-positive 
men who have sex with men (MSM) has been high for >10 years. In 2015 DAA became 
available to all Dutch HCV patients and resulted in a rapid treatment uptake in HIV-positive 
MSM. We assessed whether this uptake was followed by a decrease in the incidence of 
HCV infections in HIV-positive MSM.  
Methods 
Two prospective acute HCV treatment studies enrolled patients in 17 Dutch HIV centers, 
having 76% of the total HIV-positive MSM population in care in the Netherlands. Patients 
were recruited in 2014 and 2016, the years preceding and following unrestricted DAA 
availability. We compared the HCV incidence in both years.  
Results 
The acute HCV incidence decreased from 93 infections during 8290 person years of follow 
up in 2014 (11.2/1000 PYFU, 95% CI 9.1-13.7) to 49 during 8961 PYFU in 2016 (5.5/1000, 
95% CI 4.1–7.2). The incidence rate ratio of 2016 compared with 2014 was 0.49 (95% C.I. 
0.35-0.69). Simultaneously, a significant increase in the percentage positive syphilis (+2.2%) 
and gonorrhea (+2.8%) tests in HIV-positive MSM was observed at sexual health clinics 
across the Netherlands and contradicts a decrease in risk behavior as an alternative 
explanation.  
Conclusions  
Unrestricted DAA availability in the Netherlands was followed by a 51% decrease in acute 
HCV infections among HIV-positive MSM.  
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Background           
 
A high incidence of acute hepatitis C (HCV) infections in HIV-positive men who have sex 
with men (MSM) has been observed in many European countries as well as in Australia and 
the United States1-3. Indeed, during anal intercourse and additional high risk behavior with 
increased likelihood of blood-blood contact, HCV can be readily transmitted from man to 
man4. This contrasts with the very low incidence of transmission during heterosexual 
contacts5. Several recent studies described an acute HCV incidence in Dutch HIV-positive 
MSM of 1.1% or 11/1000 person years of follow up (PYFU)6-8. This is an extremely high 
incidence in a country where the overall HCV prevalence is estimated at 0.2%.9 Van Santen 
et al. described a comparably high incidence of acute HCV among HIV-positive MSM in 
several other European countries10.  
 
As of July 2014, interferon free HCV therapy with direct acting antivirals (DAA) became 
reimbursed for all Dutch inhabitants with chronic HCV induced severe liver fibrosis or 
cirrhosis. At that time, the very high costs of these drugs were the reason why DAA therapy 
did not became available to all patients infected with HCV. Eventually, the restriction to 
patients with severe liver disease was lifted on November the 1st 2015. As a result, the 
Netherlands was one of the first European countries in which DAA therapy became 
available to all chronically HCV infected patients without any restrictions.  
 
We recently showed that the unrestricted DAA availability was followed by a very rapid HCV 
treatment uptake among HIV-positive MSM with chronic HCV. Indeed, already 76% of the 
Dutch HIV-positive MSM ever infected with HCV were shown to be cured of their HCV 
infection as of January 201711. Mathematical modeling studies have predicted that by 
decreasing the pool of infectious persons in the population, the immediate treatment with 
DAA of all HCV infected HIV-positive MSM would lead to a progressive decline in the 
incidence of acute HCV infections12-14. However, this assumed decline in incidence has yet 
to be confirmed with real life observational data.  
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Therefore, the aim of this study was to investigate whether the countrywide rollout of DAA 
was followed by a decline in the number of acute HCV infections among HIV-positive MSM 
within the Netherlands.  
 
Patients and methods         
 
According to Dutch HIV treatment guidelines, HCV infections in HIV-positive MSM attending 
the HIV outpatient clinic are diagnosed by HCV antibody testing (followed by HCV RNA 
testing when antibodies are positive) at entry into HIV care. Thereafter, HCV IgG testing is 
performed once a year and, HCV RNA testing is also done if a new alanine aminotransferase 
(ALT) elevation is observed. Liver enzymes are measured during the biannual HIV viral load 
monitoring.  
An acute HCV infection was defined as a positive HCV RNA test, preceded by a negative 
HCV test in the previous 12 months. Because HIV centers in the Netherlands store leftover 
plasma from each outpatient visit, retesting of superfluous plasma from the preceding 
outpatient visit was possible in the majority of the patients to confirm that the patient had 
been HCV-negative in the previous year. However, if stored plasma was not available, a 
new HCV diagnosis was also considered to be an acute HCV infection if a normal ALT 
measurement within the last 12 months preceded the first positive HCV-RNA test and a 
documented negative HCV test was available from any time in the past and no other 
possible explanation for the ALT elevation was found15. 
An acute HCV re-infection was defined as a positive HCV RNA test after a previously 
documented sustained virological response 12 weeks or more after the end of HCV 
therapy. For patients treated in the Dutch Acute HCV in HIV Studies (DAHHS), in case HCV 
RNA became detectable again within 12 weeks after the end of therapy, HCV RNA was also 
genotyped and sequenced to differentiate relapse from reinfection.  
Currently there is no systematic registry in place for acute HCV infections in the 
Netherlands. We therefore used the data from two prospective studies as a proxy. The 
DAHHS-group is a network of 17 hospitals that performs multicenter clinical trials on the 
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treatment of AHCV16,17. None of the currently available DAA have been registered for the 
treatment of an acute HCV infection. Therefore and to evaluate the effectivity of DAA for 
the treatment of acute HCV, the DAHHS1 and 2 studies were designed. Both are 
prospective studies that evaluated (DAHHS1 in 2014) or are evaluating (DAHHS2 in 2016 
and ongoing) different DAA-based options for the treatment of acute HCV infection. 
Because these studies enroll(ed) patients prospectively they enabled us to register all acute 
HCV infections diagnosed in the DAHHS centers and compare the incidence of acute HCV 
infections among HIV-positive MSM in the year preceding (2014) and in the first year after 
(2016) interferon free DAA became available for the treatment of chronic HCV in the 
Netherlands. 
Patient characteristics were collected by the treating physician and transferred to the study 
coordinator after pseudonymization. All patients consented to have their data used for 
research purposes in the context of the HIV ATHENA cohort18. Data on the number of HIV-
positive MSM and on the HCV prevalence among HIV-positive MSM in care across all HIV 
centers in the Netherlands were provided by Stichting HIV Monitoring (SHM, HIV 
Monitoring Foundation), responsible for data collection of the patients in the ATHENA 
cohort. The ATHENA cohort consists of 98% of the patients diagnosed with and in care for 
HIV in the Netherlands18. 
The incidence of acute HCV in the year 2014, the last year before DAA became available 
and 2016, the first year after unrestricted DAA availability was calculated by dividing the 
number of acute HCV cases by the PYFU of all HIV-positive MSM in that year in the 17 study 
centers. To compare the acute HCV incidence in 2016 with 2014, we calculated the 
incidence rate ratio (IRR) with 95% confidence intervals.  
Because HCV infections are transmitted sexually among MSM, national data on the 
incidence of the sexually transmitted diseases (STDs) syphilis and gonorrhea in MSM were 
used as a surrogate marker for the evaluation of possible trends in sexual risk behavior. 
These data are provided by the STD/HIV Surveillance Unit of the National Institute for 
Public Health and Environment (RIVM). The RIVM collects, integrates and interprets data 
from multiple surveillance sources in the Netherlands, including data from registration by 
sentinel STD clinics and HIV treatment centers19,20.  
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Results            
 
In 2014, 93 acute HCV infections were diagnosed in the 17 study centers during 8290 PYFU 
(incidence of 11.2/1000 PYFU, 95% CI 9.1-13.7). In contrast, 49 acute HCV infections were 
diagnosed during 8961 PYFU in 2016 (incidence of 5.5/1000 PYFU, 95% CI 4.1–7.2). Thus, 
the incidence rate ratio of 2016 compared with 2014 was 0.49 (95% C.I. 0.35 - 0.69). During 
the first 4 months of 2017, the incidence was 5.6 per 1000 PYFU (17/3047 PYFU) and 
comparable to the overall incidence in 2016. In 2014, the majority of acute HCV infections 
was caused by HCV genotype 1 (72/93; 77%). The proportion of genotype 1 in acute HCV 
infection decreased in 2016 (27/49; 55%) (figure 1). Consequently, the incidence rate ratio 
for genotype 1 infections comparing 2016 to 2014 was 0.35 (95% CI 0.22-0.54). Looking at 
the smaller group of genotype 4 infections only, the decline was less pronounced and not 
statistically significant (IRR 0.77; 95% CI 0.54-1.09). A change in the distribution of the 
nation of origin of the patients diagnosed with an acute HCV of the genotype 1 or 4 could 
not explain the difference in decline in the incidence of genotype 1 and 4. Indeed, 23/93 
patients with an acute HCV diagnosed in 2014 were born outside the Netherlands which 
was comparable to 2016 (8/49, p=0.29). Figure 2 illustrates the incidence of acute HCV for 
every 4 months of the calendar year and per genotype in 2014, 2016 and the first 4 months 
of 2017.  
 
Figure 2 Left axis Acute HCV infections per 4 months and per genotype Right axis Percentage HCV 
RNA positive HIV-positive MSM (blue) and number of HCV treatments (red) in the Netherlands per 
year (both personal communication SHM). 
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Figure 1 HCV infections in HIV-positive MSM in care in the Netherlands 
A Percentage of HIV-positive MSM in the Netherlands that remained HCV RNA positive in 2014 and 2016 
B Acute HCV infections in 2014 and 2016 
  
Chapter 5 
94 
 
Table 1 Baseline characteristics of patients with an acute hepatitis C infection in 2014 and 2016 
 
 
2014 2016 p-value 
Acute HCVa infections n=93 n=49 
 
Age in years (mean +- SD) 42 (± 9) 46 (± 9) 0.06 
On cARTb (%) 84 (90) 43 (94) 0.53 
CD4 cells/mm3 (median, IQR) 610 (430-810) 620 (465-763) 0.86 
Reinfection (%) 21 (23) 12 (25) 0.75 
HCV genotype (%) 
genotype 1 
 
72 (77) 
 
27 (55) 
0.02 
genotype 2 2 (2) 1 (2) 
 
genotype 3 0 2 (4) 
 
genotype 4 18 (19) 15 (31) 
 
Missing 1 (1) 4 (8) 
 
HCV genotype 1 
subtype a 
 
68 
 
27 
0.57 
subtype b 4 0 
 
 
The absolute number of acute HCV infections decreased both in patients with a first acute 
HCV infection and in patients that had an acute HCV reinfection after a previously cured 
HCV infection, while the proportion of reinfections remained constant between 2014 and 
2016 (23% (21 of 93) and 24% (12 of 49), respectively) (p=0.8) (table 1).  
In the years that preceded the introduction of DAA, the proportion of HIV-positive MSM in 
the Netherlands who were HCV RNA positive (and thus a potential source for new 
infections) was stable at 4,2 % in 2013 (396/9513) and 4,1% in 2015 (450/11070). The 
unrestricted access to DAA caused a prompt and substantial decrease of this infectious 
pool to 1.5% (176/11749) by the end of 2016 (data provided by SHM; figure 1). When 
comparing 2016 to 2014, a substantial increase in the percentage of positive syphilis (from 
6.6% to 8.4%; resp. 281/4240 and 435/5185; p=0.001) and gonorrhea tests (from 16.4% to 
19.2%; resp. 697/4239 and 1005/5228; p<0.001) among HIV-positive MSM attending 
sentinel STD clinics in the Netherlands was observed19,20. 
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Discussion            
 
We observed a 51% decrease in acute HCV infections in 2016 compared to 2014. As far as 
we know, this is the first study that uses real-life data that lends support to what recent 
modeling studies have predicted; universal HCV therapy of all HIV-positive MSM chronically 
infected with HCV will result in a decrease in the number of acute HCV infections in this 
population12-14.  
The decline of acute HCV infections was more pronounced for HCV genotype 1 (65% 
decrease) than for genotype 4 (23%). Possibly treatment of acute HCV infection in the 
context of the DAHHS1 study (only HCV genotype 1 infections could be treated in this 
study) may explain the more substantial decrease of genotype 1 than 4 infections that we 
observed. Indeed, as much as 79% of the 72 patients diagnosed with an acute HCV 
genotype 1 infection in 2014 in the 17 study centers were treated in the DAHHS1 study and 
86% of them were cured and therefore no longer a source of new genotype 1 
infections15,16. However, the chronic HCV treatment uptake among Dutch HIV-positive 
patients in general did not differ between genotype 1 and 4 and neither was there a 
difference in uptake in relation to the country of origin of these patients, so a disparity in 
HCV treatment uptake based on country of origin or genotype cannot explain the smaller 
decrease in incidence of acute HCV of the genotype 4 compared with genotype 1. It is well 
known that acute HCV outbreaks occur frequently and this may have been the case for 
genotype 4. Indeed, as illustrated in figure 2, 80% of the genotype 4 infections in 2016 
were diagnosed in the first 4 months of 2016.  
The incidence of HCV reinfection among HIV positive MSM that were cured of a previous 
HCV infection has historically been very high21. Therefore, this subgroup of patients may be 
at the core of the HCV epidemic. To this regard, it is reassuring that we observed a 
decrease in the number of HCV reinfections as well (from 21 to 12), despite a substantial 
increase in the population at risk for reinfection. Indeed, as a result of the HCV treatment 
uptake and the consequent decline of HCV RNA positive patients from 4.2% in 2013 to 1.5% 
at the end of 2016, the number of patients that were cured of HCV and therefore become 
at risk for a reinfection has increased substantially. 
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In contrast to the decline in acute HCV infections, the number of MSM diagnosed with 
syphilis or gonorrhea at STD clinics across the Netherlands increased substantially in 2016. 
Therefore, it is very unlikely that the decline in acute HCV infections that we observed is the 
result of reduced sexual risk behavior.  
In 2015, Vanhommerig et al. found that in HIV-positive MSM, receptive unprotected anal 
intercourse, sharing sex toys, unprotected fisting and a recent diagnosis of ulcerative STDs 
were all independent risk factors for the acquisition of acute HCV infection4. Also, 
intravenous drug use (IVDU) before or during sex (also called slamming or slamsex) was 
another significant risk factor. However, only 11% (9 of 82) of the patient with an acute 
HCV infection included in their study reported IVDU as a risk factor. Therefore, we consider 
it unlikely that a decrease in IVDU among HIV-positive MSM in 2016 compared with 2014 
can explain our observations. Second, a recent study into Q80K phylogeny in Dutch HCV 
genotype 1a infected patients showed no intermingling of HIV-positive MSM and PWID22. 
Although injection drug use (whether IV or subcutaneously) during sex does occur in a small 
number of HIV-positive MSM4 and sexual networks seem to be highly dynamic23, it is 
unlikely that HCV strains from Dutch PWID fuel the HCV epidemic in Dutch HIV-positive 
MSM22.  
The strength of our study is the prospective data collection on acute HCV incidence in 17 
HIV centers. These 17 centers are representative for the whole of the Netherlands as they 
are located in all major Dutch cities and provide HIV therapy to more than 75% of all HIV-
positive MSM in care in the Netherlands.  
Our study has several limitations. First, an observational study cannot prove that the DAA 
uptake is the cause of the decline in acute HCV incidence. A substantial change in risk 
behavior may have led to a similar decrease. We did not measure IVDU in our cohort, 
however, as stated above, IVDU does not appear to be an important risk behavior in Dutch 
HIV positive MSM although this may change over time. Second, from modeling studies in 
PWID it is known that treatment scale up can have a bigger impact on a stable versus an 
increasing HCV epidemic24. In contrast to the stable HCV incidence in HIV-positive MSM in 
the Netherlands, other parts of Europe still see a rising incidence of HCV infections10, thus 
treatment scale up might not have the same effect on those epidemics. Therefore, the 
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extrapolation of our data to other settings should be done with caution. Third, the 
proportion of chronically HCV infected patients, whom are very unlikely to be diagnosed 
with a new acute HCV superinfection (as they are already HCV RNA positive) was not 
subtracted from the total PYFU of HIV-positive MSM in the incidence calculations. 
However, excluding them from the IRR calculation would further lower the IRR from 0.49 to 
0.47. Fourth, by the end of 2015 a certain number of MSM were living with HIV but where 
unaware of their HIV infection and therefore not in care. As such, our conclusions cannot 
be extrapolated to this HIV infected MSM population. However, in the Netherlands this 
fraction has been estimated to be small at around 10%25. Finally, acute HCV infections 
often occur in localized outbreaks and therefore, temporary fluctuations in the incidence 
can be expected. Therefore, longer-term data are needed to confirm that the decrease we 
have observed is not the result of an extreme fluctuation by chance. 
Although the 51% decrease of acute HCV infections we describe is encouraging, it is very 
unlikely that DAA therapy for all HCV co-infected patients with HIV as a single intervention 
will lead to elimination of HCV among Dutch HIV-positive MSM12,13. Although preliminary, 
this is also suggested by the apparent lack of a further decline in incidence during the first 4 
months of 2017. Other interventions are thus needed.  
First, the incidence of acute HCV infections in HIV-positive MSM is high in major cities of all 
neighboring countries of the Netherlands26,27. Due to the continuous restrictions of DAA to 
patients with severe liver disease in some of the neighboring countries, the DAA treatment 
uptake in these countries has been limited. Therefore, cross-border HCV transmissions will 
continue to occur as long as a comparable treatment uptake does not occur in neighboring 
countries28.  
Second, while in the Netherlands the prevalence of HCV infection in HIV-negative MSM 
attending STD clinics7 and the number of reported cases of acute HCV infection in HIV-
negative MSM has been low29, the prevalence is probably substantially higher in a certain 
subset of MSM. Exemplary for this are the very recent observations in an HIV pre-exposure 
prophylaxis (PrEP) implementation project in Amsterdam. Upon entering the PrEP program 
15 patients (4%) had detectable HCV RNA30. Also, risk compensation and an increase in the 
incidence of STD during PrEP use may occur and could lead to an increase in HCV 
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transmission among PrEP users31. Therefore, we think that monitoring of the prevalence of 
HCV among HIV-negative MSM engaging in unprotected anal intercourse and in particular 
MSM using PrEP is needed.  
Third, several studies have observed an extremely high acute HCV reinfection rate in 
patients cured of a previous HCV infection26,32,33. Therefore, a specific focus on HIV-positive 
MSM with a history of a HCV infection is needed. This may consist of very frequent (e.g. 
every 3 months) HCV testing with the aim of diagnosing and treating HCV re-infections as 
early as possible34. Last, but not least, counseling on sexual risk behavior is important and 
when appropriate, referral to specialized clinics for problematic recreational drug use in the 
context of chemsex or slamsex is needed13 as not only IVDU but also orally administrated 
drugs seem to be associated with HCV transmission among HIV-positive MSM4. 
In conclusion, a 51% decrease of acute HCV infections in HIV-positive MSM was observed in 
2016 compared to 2014. A HCV “treatment as prevention” effect that was caused by the 
rapid DAA treatment uptake among HIV-positive MSM with chronic HCV is the most 
plausible explanation for this decline.  
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Research in context          
 
What was known on this topic? 
Sexually acquired acute hepatitis C infection used to be regarded as limited to HIV-positive 
men who have sex with men. Several large cohort studies showed a very low prevalence in 
HIV-negative men who have sex with men, comparable to the HCV prevalence in the 
general population. 
What does this add? 
With this case series we want to raise awareness among a broad range of Dutch clinicians. 
Sexually transmitted hepatitis C infection seems to be no longer limited to HIV-positive 
MSM, at least a subgroup of HIV-negative MSM are probably at increased risk.  
With the advent of pre-exposure prophylaxis (PrEP; protects against HIV infection), 
clinicians should be aware of the possibility of acute HCV infections in HIV-negative MSM 
and at least surveillance should be in place to gain inside the prevalence and incidence 
among this risk group.  
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Abstract            
 
Background  
The evidence that HIV treatment as prevention (TaSP) and HIV pre-exposure prophylaxis 
(PrEP) reduces the risk of HIV transmission is overwhelming. But as PrEP and TaSP can lead 
to increased sexual mixing between HIV positive and negative MSM, sexually transmitted 
infections like HCV that were thought to be limited to HIV infected MSM could become 
more frequent in HIV uninfected MSM as well. The objective of this study was to describe a 
series of cases of sexually transmitted HCV infections in HIV-uninfected MSM in the 
Netherlands and Belgium.  
Methods  
Through the Dutch Acute HCV in HIV Study (a Dutch-Belgian prospective multicentre study 
on the treatment of acute HCV infection, NCT02600325) and the Be-PrEP-ared study (a 
PrEP project in Antwerp, EudraCT2015-000054-37) several acute HCV infections were 
detected in HIV-negative men.  
Results  
A newly acquired HCV infection was diagnosed in ten HIV-negative MSM. HCV was 
diagnosed at a sexually transmitted infection (STI) clinic (n=2), by their general practitioner 
(n=2), by their HIV physician (n=1) or at a PrEP clinic (n=5). Ten patients reported 
unprotected anal intercourse and four had a concomitant STI at the time of HCV diagnosis. 
Six patients reported using drugs during sex.  
Conclusions  
Our observation calls for a larger nationwide epidemiological study on the prevalence, 
incidence and risk factors of HCV infection in HIV-uninfected MSM. In the changing 
landscape of TasP and PrEP, reliable and up-to-date epidemiological data on HCV among 
HIV-uninfected MSM are needed and will help in developing evidence-based testing 
policies.  
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Introduction           
 
The World Health Organization recently released targets for hepatitis B and hepatitis C 
(HCV) elimination by 2030. They are comprised of a 90% reduction in new infections and a 
65% reduction in hepatitis-related mortality by 20301. One of the key populations at risk for 
HCV infection are HIV-infected men who have sex with men (MSM). Among HIV-infected 
individuals worldwide, it has been estimated that 2.4% are co-infected with HCV, yet this 
rises to 6.4% in HIV-infected MSM2. Because HIV-infected MSM in Western-Europe are in 
care for their HIV, treating all HIV-infected patients with an HCV co-infection for their HCV 
should be straightforward and HCV elimination in this specific subgroup might be 
possible3,4. Previous epidemiological data suggested that transmission of HCV among MSM 
was largely limited to HIV-infected MSM5-7. 
 
The evidence that HIV treatment as prevention (TaSP) and HIV pre-exposure prophylaxis 
(PrEP) reduces the risk of HIV transmission is overwhelming8-11. Although currently only 
four European countries have made PrEP available free of charge, generic tenofovir-
disoproxil fumarate and emtricitabine in a single combination tablet are becoming available 
in certain European countries soon12. In Germany as well as the Netherlands negotiations 
have resulted in a substantial price reduction and will make PrEP affordable for many MSM.  
 
Without any doubt, PrEP and TaSP will prevent many new HIV infections in MSM. However, 
it can be expected that PrEP and TaSP will also lead to increased sexual mixing between HIV 
positive and negative MSM. As such, sexually transmitted infections (STI’s) like HCV that 
were thought to be limited to HIV infected MSM are likely to become more frequent in HIV 
uninfected MSM as well. A recent modelling study seems to confirm this and showed that 
sexual behaviour patterns are likely to drive the HCV infection pattern among HIV-positive 
MSM. If changes in these patterns occur, they could lead to HCV dissemination amongst 
HIV negative MSM and may decrease the impact of unrestricted HCV treatment for HIV-
infected MSM on the HCV epidemic in MSM in general13.  
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Very recently, Hoornenborg et al. showed that at the start of the Amsterdam PrEP study, 
the prevalence of HCV infection was 4% as 15 of the 375 MSM were chronically infected 
with HCV 14. This illustrates that in a subgroup of HIV-uninfected MSM, the prevalence of 
HCV infection may be very substantial and this contrasts with what has been reported 
earlier about the HCV prevalence and incidence in HIV-negative MSM6,15. 
 
The objective of this study was to describe a series of cases and therefore create increased 
awareness about newly acquired HCV infections in HIV-uninfected MSM in the Netherlands 
and Belgium. All had tested HCV negative in the recent past.  
 
Methods            
 
Cases of HIV-negative MSM with a newly acquired HCV infection were collected in the 
context of an acute HCV treatment study (the Dutch-Belgian prospective multicentre study 
on the treatment of acute HCV infection (DAHHS-2, NCT02600325) or within an PrEP-
project in Antwerp (Be-PrEP-ared; EudraCT2015-000054-37). Patients were initially 
diagnosed by their GP, their STI clinic, their HIV specialist or the PrEP project before they 
were referred to the DAHHS 2 study team. 
 
 All reported patients had been tested negative for HCV in the recent past. Patients were 
screened for HCV for different reasons in different settings as stated above and in table 1. 
HCV testing was done according to the local standard of care, which in all cases consisted of 
screening for HCV with HCV antibodies. Acute HCV was defined as a positive anti-HCV 
immunoglobulin G and a documented negative anti-HCV IgG in the previous 12 months (1). 
Patient characteristics and risk factors were retrieved from the patient files by the treating 
physician and transferred to the study coordinators after anonymization.  
 
Both studies were approved by the institutional medical ethics committees. Enrolment in 
these studies was voluntary and a written informed consent was obtained in which the 
patients described in this report agreed that data and blood samples could be used for 
research purposes. 
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Results            
 
From 1 January 2016 to July 2017 a total of ten HIV-negative MSM with a recently acquired 
HCV infection were reported (table 1). HCV infection was diagnosed at a sexually 
transmitted infection (STI) clinic (n=2), by the general practitioner (n=2), by their 
infectiologist (n=1) or at their PrEP clinic (n=5). All patients had a documented negative HCV 
test within the year preceding the HCV diagnosis. Of the patients diagnosed at the PrEP 
clinic, one was diagnosed before the start of PrEP and four after the start of PrEP. Median 
age was 39.5 years (range 25-59). HCV genotypes 1 was found in four patients, genotype 4 
in two patients and was unknown in four patients. All patients reported unprotected anal 
intercourse (UAI), four had a concomitant STI at the time of HCV diagnosis and six reported 
drugs use during sex (chemsex). One patient reported intravenous drug use during sex 
(slamming). Clinical symptoms were non-specific or absent. Two patients were diagnosed 
after they had been informed of a HCV diagnosis in a partner. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 next page Characteristics of the 10 HIV-negative MSM with a newly acquired HCV infection  
SS: slamsex, use of intravenous drugs during sex; UAI: unprotected anal intercourse. PN: partner 
notification; CS: chemsex, use of oral drugs during sex; PrEP: pre exposure prophylaxis for HIV; PEP: post 
exposure prophylaxis for HIV; STD: sexually transmitted disease; LGV: lymphogranuloma venereum; 
SVR12: sustained virological response 12 weeks after treatment; GP: general practitioner; AIN: anal 
intraepithelial neoplasia; $:  DAHHS 2 study, NCT02600325; N/A: not applicable.  
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UAI  
CS  
SS 
4 No Chlamydia No 2016 2014 PN 
STI clinic 
Breda 
Treated after HCV 
infection became 
chronic with 
sofosbuvir 
ledipasvir 8 weeks. 
Yes 
 
UAI  1a No Non No 2016 2016 
During 
PrEP 
study 
PrEP clinic 
Amsterdam 
Grazoprevir 
elbasvir 8 weeks.($) 
Yes 
 
UAI  
CS 
Un-
detec-
table 
Fatigue 
LGV, syphilis, 
gonorrhoea, 
suspicion of 
AIN 
No 2017 2016 LGV 
STI clinic 
Rotterdam 
No, spontaneous 
clearance. 
N/A 
 
UAI  
CS 
4 
Erythema 
multiforme 
Gonorrhoea 
farynx, anal 
chlamydia 
No 2016 2015 
Routin
e 
testing 
GP from 
region 
Leuven 
Grazoprevir 
elbasvir 8 weeks.($) 
Yes 
 
UAI 
CS 
1a No Non No 2016 2016 
Routin
e 
testing 
GP from 
region West-
Flanders 
No, spontaneous 
clearance. 
N/A 
 
UAI 1a No 
Chlamydia, 
mycoplasma 
genitalium 
No 2016 2016 
During 
PrEP 
study 
PrEP clinic 
Antwerp 
(patient 
from region 
Brussel) 
Ongoing chronic 
infection.   
N/A 
 
UAI 
Un-
detec-
table 
Fatigue Non  No 2016 2016 
During 
PrEP 
study 
PrEP clinic 
Antwerp, 
(patient 
from region 
Antwerp) 
No, spontaneous 
clearance. 
N/A 
 
UAI 
CS 
Un-
detec-
table 
No 
Depression, 
post-
traumatic 
stress 
syndrome 
No 2016 2015 
During 
PrEP 
study 
PrEP clinic 
Antwerp,  
(patient 
from region 
Antwerp) 
No, spontaneous 
clearance. 
N/A 
 
UAI 
Un-
known 
Proteinuria Non  
Un-
known 
2016 2016 
Before 
start 
PrEP 
PrEP clinic 
Antwerp, 
(patient 
from region 
East-
Flanders) 
Unknown. N/A 
 
UAI 
CS 
1a Fatigue Non No 2017 2017 
PEP 
use 
Hospital, 
Eindhoven 
Grazoprevir 
elbasvir 8 weeks.($) 
N/A 
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Discussion            
 
Our case series shows that, even without an active screening policy, HCV infections are 
diagnosed in HIV-negative MSM as we were able to describe 10 cases of newly acquired 
HCV infections in Dutch and Belgian HIV-uninfected MSM. Other recent publications on 
HCV infections in HIV-negative MSM were the result of an active screening policy as part of 
an observational study or a PrEP program14,16. . Furthermore, very few studies on the 
epidemiology of HCV in HIV-uninfected MSM are available and none are collected in a way 
that incidence rates of acute HCV infection in HIV-negative MSM can be calculated to 
properly address the problem6,7,14,16-18. By design, case series cannot help to reliable 
estimate the size of the problem. We therefore call for a nationwide epidemiological study 
to get a reliable estimate of the prevalence and incidence of and insight into risk factors for 
HCV infection in HIV uninfected MSM.    
 
Not surprising, all reported unprotected anal intercourse and most had concomitant other 
STI diagnose and six used non-injection drugs during sex. These are known risk factors for 
sexual HCV-transmission in HIV-positive MSM19. In the UK, the British Association of Sexual 
Health and HIV (BASHH) recommends to at least consider testing MSM for HCV if they are 
considered at high risk for HCV infection (independent of HIV-status)20. In the Netherlands 
guidelines for the STI clinics advise testing HIV positive MSM and MSM notified for HCV, 
MSM diagnosed with a lymphogranuloma venereum infection and MSM refusing an HIV 
test21. In Belgium, there is no national guideline for HCV-testing in HIV-negative MSM. Our 
case series, together with the high prevalence of chronic HCV infection in the AmPREP 
project14, call for HCV testing of MSM at Dutch and Belgian STI clinics in order to get 
reliable data of the HCV prevalence and incidence in 2018. PrEP programs should include 
regular HCV testing and MSM who start using PrEP outside the context of an official PrEP 
program should be tested at STI clinics22. In a recently published systematic review, daily 
oral PrEP use was associated with a significant increase in rectal chlamydia and increase in 
any STI diagnosis23, which emphasises the need for STI as well as HCV prevention strategies 
for PrEP users and their partners.  
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Second, as multiple parties are involved in the care for MSM (HIV centres, STI clinics, 
general practitioners) collaboration is needed if HCV elimination is to be pursued. Last but 
not least, the development and validation of a HCV-risk score for HIV-negative MSM, as has 
been done before for HIV infected MSM, could facilitate targeted HCV testing in the 
future24.  
 
According to the definition for acute HCV infection by the European AIDS Treatment 
Network (NEAT) consensus panel(1), all our patients fulfilled the criteria for acute HCV, 
except for one patient in whom, an earlier negative test was missing. And although he was 
‘directly’ diagnosed after a recent partner notification, we cannot say for sure that he had 
an acute infection. Perhaps this patient is better defined as a recent infection according to 
definitions of Hajarizadeh et al.(2). 
 
Our case series has several limitations. Because our cases were not identified during a 
prospective surveillance study, risk factors for HCV infection cannot be identified as we 
cannot compare our cases with HCV negative controls. Furthermore, we have no 
denominator and therefore no estimate of the prevalence and incidence can be given. Also, 
we report on Dutch and Belgium cases. This is due to the fact that the acute HCV treatment 
study (DAHHS) is recruiting patients in both neighbouring countries. Although the 
healthcare systems in both countries are very alike, two important differences should be 
mentioned. In Belgium HCV therapy for patients with F0 to F2 fibrosis is currently restricted 
to patients that are HIV/HCV–coinfected, while in the Netherlands restrictions are no 
longer in place. In contrast, at the time of writing of this manuscript PrEP was available free 
of charge in Belgium but not in the Netherlands, except for a small group of MSM 
participating in the AmPREP program.  
 
In conclusion, in the changing landscape of TasP and PrEP, close monitoring of HCV 
infection among HIV-uninfected MSM is needed to improve case finding of HCV infection 
and decide upon the best testing policies of HCV infection in HIV-negative MSM.  
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Abstract            
 
Introduction  
The World Health Organization targets for hepatitis C virus (HCV) elimination include a 90% 
reduction in new infections by 2030. Our objective is to review the modelling evidence and 
cost data surrounding feasibility of HCV elimination among people living with HIV (PLWH), 
and identify likely components for elimination. We also discuss the real-world experience of 
HCV direct acting antiviral (DAA) scale-up and elimination efforts in the Netherlands. 
Methods 
We review modelling evidence of what intervention scale-up is required to achieve WHO 
HCV elimination targets among HIV-infected (HIV+) people who inject drugs (PWID) and 
men who have sex with men (MSM), review cost-effectiveness of HCV therapy among 
PLWH and discuss economic implications of elimination. We additionally use the real-world 
experience of DAA scale-up in the Netherlands to illustrate the promise and potential 
challenges of HCV elimination strategies in MSM. Finally, we summarize key components of 
the HCV elimination response among PWLH. 
Results and discussion 
Modeling indicates HCV elimination among HIV+ MSM and PWID is potentially achievable 
but requires combination treatment and either harm reduction or behavioral risk 
reductions. Preliminary modeling indicates elimination among HIV+ PWID will require 
elimination efforts among PWID more broadly. Treatment for PLWH and high-risk 
populations (PWID and MSM) is cost-effective in high-income countries, but costs of DAAs 
remain a barrier to scale-up worldwide despite the potential low production price ($50 per 
12 week course).  In the Netherlands, universal DAA availability led to rapid uptake among 
HIV+ MSM in 2015/16, and a 50% reduction in acute HCV incidence among HIV+ MSM from 
2014 to 2016 was observed.  In addition to HCV treatment, elimination among PLWH 
globally also likely requires regular HCV testing, development of low-cost accurate HCV 
diagnostics, reduced costs of DAA therapy, broad treatment access without restrictions, 
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close monitoring for HCV reinfection and retreatment, and harm reduction and/or 
behavioral interventions.  
Conclusions 
Achieving WHO HCV Elimination targets is potentially achievable among HIV-infected 
populations. Among HIV+ PWID, it likely requires HCV treatment scale-up combined with 
harm reduction for both HIV+ and HIV- populations. Among HIV+ MSM, elimination likely 
requires both HCV treatment and behavior risk reduction among the HIV+ MSM population, 
the latter of which to date has not been observed. Lower HCV diagnostic and treatment 
costs will be key to ensuring scale-up of HCV testing and treatment without restriction, 
enabling elimination.  
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Introduction           
 
Viral hepatitis was the seventh leading cause of death worldwide in 2013, increasing from 
the tenth leading cause in 20101. The vast majority of morbidity and mortality attributable 
to viral hepatitis is due to hepatitis C virus (HCV) and hepatitis B Virus (HBV). In response to 
this increasing public health challenge, the World Health Organization recently released 
targets for HBV and HCV elimination by 2030 (see table 1)2. Elimination is traditionally 
defined as a reduction to zero in the incidence of disease in a specific population or 
geographical location, with continued prevention efforts  required to prevent the re-
establishment of transmission3. Given this strict definition of elimination would require 
substantial economic and political resources and could be unattainable in most settings, 
the goal of ‘elimination’ is often flexibly defined. The recent WHO elimination “as a public 
health threat” targets are comprised of a 90% relative reduction in new infections and a 
65% relative reduction in hepatitis-related mortality by 2030.  
 
Table 1 WHO hepatitis elimination goals: impact and service coverage targets2 
 
WHO Impact Targets by 2030  
Incidence: New cases of chronic HBV and HCV  90% relative reduction 
Mortality: HBV and HCV deaths 65% relative reduction 
WHO Service Coverage Targets by 2030  
HBV childhood vaccination coverage 90% 
HBV birth dose vaccination coverage or other prevention of 
mother to child transmission initiative 
90% 
Screening of blood donations 100%  
Safe injections: % of injections administered with safety 
engineered devices in and out of health facilities 
90% 
Harm reduction: number of sterile needles and syringes provided 
per person who inject drugs per year 
300 
HBV and HCV diagnosis 90% 
HBV and HCV treatment 
 
80% of persons with chronic 
infection treated 
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Hence, to achieve the WHO incidence elimination targets, efforts must focus on both 
prevention of disease and prevention of transmission. The advent of highly-effective HCV 
DAA therapy, with sustained viral response (SVR) exceeding 90% in both HCV monoinfected 
and HIV/HCV coinfected populations4-8 has renewed optimism that substantial reductions 
or elimination of end stage liver disease and HCV-related mortality is a possibility. The 
widespread use of HIV antiretroviral treatment for prevention has also led to speculation 
that HCV treatment could also be used for prevention. Additionally, among people who 
inject drugs (PWID), a key risk group for HCV, harm reduction interventions such as opiate 
substitution therapy (OST) and needle and syringe programs (NSP) have been the 
traditional backbone of HCV prevention. A recent Cochrane systematic review9 found that 
OST reduces risk of HCV acquisition by 50% (risk ratio 0.50 95% CI 0.40-0.63) and combined 
with high coverage of NSP results in a 71% reduction in the risk of HCV acquisition (Risk 
Ratio=0.29 95% CI=0.13-0.65).  
 
The WHO strategy does not include discussion relating to elimination of viral hepatitis 
among HIV-infected populations specifically. Yet, because of the shared transmission routes 
many people living with HIV (PLWH) are coinfected with viral hepatitis. Globally, 
approximately 6.2% (3.4-11.9%) of PLWH are coinfected with HCV, equating to 
approximately 2.28 million (IQR 1.27-4.42) HIV/HCV coinfected individuals10.  Indeed, 
people living with HIV (PLWH) are six times more likely to be infected with HCV compared 
to those not infected with HIV.  The burden of HIV-HCV coinfection is particularly high 
among high risk groups such as men who have sex with men (MSM) and people who inject 
drugs (PWID).  Among HIV-infected individuals worldwide, it has been estimated that 2.4% 
(IQR 0·8-5·8) are coinfected with HCV within general population samples, yet this rises to 
6.4% (3.2-10.0) in men who have sex with men (MSM), and 82.4% (55.2-88.5) in people 
who inject drugs (PWID)10. As such, to achieve the WHO HCV elimination incidence 
reduction target among PWLH it is crucial to tackle transmission among HIV-infected MSM 
and PWID. However, although the prevention interventions required to eliminate HCV 
globally will be equally applicable to coinfected populations, the intervention level required 
and targeting may be different based on specific epidemic characteristics.   
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The objective of this paper is to review the modelling and cost evidence surrounding 
feasibility of HCV elimination among HIV-infected (HIV+) key populations such as men who 
have sex with men (MSM) and people who inject drugs (PWID) and identify the likely 
components required for HCV elimination among PLWH. We use the real world experience 
of HCV direct acting antiviral (DAA) scale-up in the Netherlands through the Dutch Acute 
HCV in HIV Studies to illustrate the promise and potential challenges of HCV elimination 
strategies in a key population (MSM).  
 
Methods            
 
This analysis is comprised of four parts:  
 
1. A review of the theoretical mathematical modeling literature examining what 
prevention and treatment scale-up is required for HCV elimination among HIV-
infected PWID and HIV-infected MSM populations.  
2. A review of the cost-effectiveness of HCV treatment for HIV-infected populations 
and discussion of cost considerations for elimination.  
3. A discussion of the real-world experience of HCV DAA scale-up among HIV+ MSM in 
the Netherlands  
4. A summary of probable and possible components of the HCV elimination response 
among PWLH.  
 
Results and discussion         
 
Modeling the scale-up needed for HCV elimination among HIV-infected populations 
 
1. HIV-infected people who inject drugs (PWID) 
Numerous burden of disease models have shown that existing or modestly increased levels 
of treatment targeted at individuals with more advanced liver disease can achieve the WHO 
HCV mortality target (65% reduction by 2030) in a variety of global settings. For example, a 
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regional European Union model showed that HCV treatment only need to increase from 
150,000 patients in 2015 to 187,000 patients in 2025 to achieve the mortality elimination 
target11.   A separate multi-country analysis including some resource limited settings found 
that achieving the WHO HCV mortality target in Hungary, Indonesia, Lebanon, Pakistan, and 
Romania is unlikely to be achieved with existing screening/treatment programs, but could 
be achieved with scaled-up screening and treatment12. These models of disease 
progression are particularly valuable in identifying the level and targeting of treatment 
required to reduce HCV mortality, but because they do not mechanistically incorporate 
disease transmission are unable to shed light on what is required to achieve the WHO 
incidence elimination target. 
 
A wide body of literature since 2011 has utilized epidemic modeling to explore what level 
of prevention scale-up could result in control and elimination among PWID, and whether 
HCV treatment could be used for prevention. Several initial modeling studies in the UK and 
general PWID populations of varying prevalences have indicated that harm reduction alone 
is unlikely to achieve HCV elimination among PWID populations13,14. Subsequent studies 
have explored the potential of HCV treatment as prevention among PWID populations in a 
range of settings including North America, Europe, Asia, and Australia13,15-20. Broadly 
speaking, these studies have generally found that scale up of HCV treatment to rates to 
below 100 per 1000 PWID annually, particularly in combination with harm reduction13,16,21, 
can reduce HCV incidence by 90% by 2030 across a wide range of settings. Results have 
been consistent between high and low income settings examined, such as Vietnam20.  
 
Additionally, modeling studies have pointed to several key additional elements which are 
required for achieving elimination among PWID: One Australian study highlighted the need 
for enhanced HCV screening among PWID in order to sustain HCV treatment rates required 
for elimination, a situation which is likely applicable to many global settings22. Additionally, 
a modeling study in the rural U.S. emphasized the importance of retreatment of reinfection 
in achieving elimination targets21. As such, elimination strategies likely require regular 
testing22, HCV treatment13,15-20, harm reduction13,16,21, and retreatment of reinfections21. 
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Despite several studies modeling HIV and HCV coinfection transmission among PWID23,24, to 
our knowledge as of 2017 no published study has explored what is required for HCV 
elimination among HIV-infected PWID in particular. Preliminary modeling presented at a 
recent international conference indicated that HCV treatment targeted at HIV-infected 
PWID in Andalusia, Spain would not achieve elimination among this population due to 
continued risk of HCV transmission from HIV-negative PWID populations25. Therefore, more 
generally, because the burden of HCV is high among HIV-uninfected PWID populations, and 
as HIV-infected PWID populations are likely to mix with HIV-uninfected PWID populations, 
elimination among HIV-infected PWID is probably only achievable if combination HCV 
prevention efforts are targeted both HIV+ and HIV- PWID populations.  
 
2. HIV-infected men who have sex with men (MSM) 
An HCV epidemic among HIV-infected MSM has been observed in the United States, 
Western Europe, Australia, Taiwan, Hong Kong, and Japan, with HCV incidence and 
prevalence among HIV-infected MSM substantially higher than the HIV-uninfected MSM 
population26,27. A growing number of modeling studies since 2015 have explored what level 
of intervention (treatment and/or risk reduction) is required to eliminate HCV among HIV-
infected MSM populations28-31. To date, these studies have focused exclusively on Western 
European settings (UK, Switzerland, Berlin, and the Netherlands), and no studies have 
explored resource limited settings, in part because of the lack of epidemiological data on 
HCV epidemics among HIV+ MSM in these settings. However the specific epidemic 
characteristics between the modelled settings has varied. One unifying characteristic is the 
relatively low rates of primary incidence among HIV+ MSM (1-2 per 100 person-years26,32) 
compared to PWID populations but high rates of reinfection (2-10 fold that of primary 
incidence33-35 ) Together these could pose a challenge for elimination efforts, where a 
relative reduction of 90% would translate to very low targets (0.1-0.2/100 person-years) 
which could be particularly hampered by high rates of reinfection. Nevertheless, the 
absolute numbers of HCV-HIV coinfected MSM are small, most diagnosed HIV+ MSM are 
linked to care in high income settings where HCV epidemics among HIV+ MSM have been 
documented 36-38 so HCV elimination may be particularly feasible in this group. 
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As with PWID, modeling indicates the level of intervention required among HIV+ MSM to 
achieve the WHO elimination targets varies by epidemiological setting, particularly given 
substantial variation of incidence trends. For example, among HIV+ MSM incidence of HCV 
over the past decade has remained relatively stable in the UK and the Netherlands.   In the 
UK, a modeling study indicated that scaled-up rates of DAA therapy (from 46% to 80% 
treated within a year of diagnosis and from 7%/year to 20%/year thereafter) could reduce 
incidence among HIV+ MSM over 60% by 2030, but could not meet elimination targets28. 
Elimination targets could be reached when all those diagnosed receive treatment within 1 
year of diagnosis, or if treatment scale-up is combined with a behavioral risk reduction25. 
 
By contrast, HCV incidence among HIV+ MSM has steadily increased over the past decade 
in Switzerland and Germany. In Switzerland, this has occurred alongside an increase in self-
reported risk behavior (unprotected anal intercourse). A recent modeling study in 
Switzerland projected that if these trends continue, elimination (or even reductions in HCV 
incidence) could not be achieved through HCV treatment alone, and requires additional 
reduction of high risk behavior (perhaps through behavioral interventions)29. Preliminary 
modeling in Berlin supports the Swiss findings. Germany is a unique setting in that universal 
access for DAAs has been available since 2014, and as such relatively high treatment rates 
(>80% HIV+ MSM treated after their acute diagnosis) have been achieved. However, the 
continued increase in HCV incidence among HIV+ MSM in Berlin and Germany overall (from 
0.33/100py in 1996-1999 to 2.28/100py in 2008-2012 in Germany39) and high levels of 
reinfection (7-8 per 100 person-years33) mean that elimination by 2030 likely requires both 
further scale-up of HCV treatment and reductions in high risk behavior31. 
 
Finally, preliminary modeling in the Netherlands indicated immediate treatment of all 
diagnosed HIV+ MSM with DAAs could only result in moderate reductions in HCV incidence 
among HIV+ MSM (~30% within 15 years), but not reach WHO elimination targets30. 
However, the real-world observation of a halving of HCV incidence among HIV+ MSM from 
2014 to 2016 with expansion of DAA therapy as described below has raised excitement 
about the potential for elimination via treatment as prevention among HIV+ MSM in the 
Netherlands, described later in this paper. 
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Cost and cost-effectiveness implications of HCV testing and treatment scale-up for 
elimination among HIV-infected populations 
 
There is a wide body of evidence that HCV treatment is cost-effective for HIV-infected 
populations, including HIV+ MSM with a risk of reinfection, 40-44 in high income settings 
such as the United States and the UK. Additionally, as mentioned previously, achieving HCV 
elimination among key risk groups such as HIV+ PWID, may require targeting the broader 
PWID population. Numerous economic evaluations have shown that HCV treatment is cost-
effective for PWID populations in high-income settings 45-53 despite the potential risk of 
reinfection and higher mortality rates among PWID populations. Indeed, economic 
evaluations indicate treating PWID with an ongoing risk of transmission may accrue 
substantial economic benefits through prevention of transmission. Additionally, an 
economic analysis in Australia found that HCV treatment scale-up to achieve the WHO 
targets among PWID was cost-effective15. Unfortunately, no cost-effectiveness studies for 
HIV-infected populations or PWID have been performed in resource limited settings. 
However economic analyses have shown that DAA therapy for the general population is 
cost-effective India54 and Egypt55,56 where generic or low cost DAAs are available.   
Despite the evidence HCV treatment is cost-effective, the high costs of HCV treatment 57 
(>$75,000 per 12 week treatment course for sofosbuvir+daclatasvir in the US and UK) 
remain a major barrier to HCV treatment scale-up. Prices vary widely depending on country 
and income status57, and prices of innovator and generic medicines have fallen, but 
nevertheless remain prohibitively high for widespread scale-up in developed and 
developing countries alike.   
 
Unfortunately, the high costs of HCV treatment have so far resulted in prioritization of HCV 
therapy (or restrictions on insurance reimbursement) even in developed countries58,59. In 
these settings, patients with more advanced liver disease and those coinfected with HIV 
have traditionally been prioritized for early treatment. Although this type of strategy will be 
effective in preventing HCV-related morbidity and mortality among PWLH, it undermines 
elimination efforts as PLWH will remain at risk of being infected or reinfected with HCV 
from individuals who remain untreated and are at risk of transmitting. For example, PWID 
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with a risk of transmission tend to be younger with less advanced liver disease, and 
therefore prioritization strategies targeting individuals with advanced liver disease may fail 
to prevent the substantial amount of transmission from this group60. This is despite 
economic assessments indicating that treatment scale-up among PWID at or below the 
level required for elimination is cost-effective in settings like Australia, the UK, and 
Netherlands15,60,61. Additionally, models indicate early treatment for PWID is cost-effective 
compared to delay until cirrhosis, and may be more cost-effective than early treatment for 
those with no ongoing risk in settings with low-moderate (20/40%) HCV prevalence among 
PWID due to substantial prevention benefits of early treatment of PWID60.  Unfortunately, 
no economic evaluations have assessed whether scaled-up treatment to achieve HCV 
elimination among PWID is cost-effective in resource-limited settings.  
 
However, although HCV therapy is likely cost-effective, the high costs per treatment results 
in a substantial budgetary impact in countries with a large HCV infected populations. This 
has resulted in HCV treatment restrictions even in resource rich countries in the U.S. and 
Europe58,59. Indeed, HCV treatment coverage is still low globally62. A recent analysis 
estimated that the percentage of people with HCV who were treated with DAAs in 2016 
ranged from 8.1% in North America and North Africa/Middle East to 0.1% in sub-Saharan 
Africa63.  Among 91 countries analyzed, 47 countries had more new HCV infections than 
individuals who achieved cure through HCV treatment in 201663, indicating that these 
countries are failing to turn off the tap of new infections with treatment. Nevertheless, 
some countries are achieving very high treatment rates among specific subpopulations, 
such as among HIV+ MSM in the Netherlands, discussed in the next section. 
 
Promisingly, HCV DAA therapies could be produced as generics at a fraction of the current 
costs64, particularly from within a country such as India due to its sizeable generic industry 
and low production costs. A recent analysis estimated the costs of generic HCV DAA 
production based on the costs of their active pharmaceutical ingredients. This analysis 
found that the combination treatment sofosbuvir and daclatasvir has an estimated generic 
cost of $50-72 per 12-week course with a 10-50% profit margin (Hill A, unpublished results).  
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Additionally, even the costs of HCV diagnosis and monitoring remain prohibitive in many 
developing countries65. For example, in India, generic HCV treatments are available for at or 
below $300 per treatment course, yet HCV antibody and RNA testing costs an estimated 
$17 and $108, respectively66. Additionally, with current treatment monitoring as suggested 
by the Indian national guidelines 67(every 4 weeks with RNA tests at week 0, 12, and SVR12) 
the cost of treatment delivery could easily far exceed that of HCV treatment.  
 
Finally, in many settings additional financing will be required to build the capacity of health 
services for diagnosis and treatment of HCV. However, the economic implications of this 
health systems strengthening (in terms of increased personnel, training, infrastructure, etc) 
has not been estimated. It is possible that integration of HCV testing and treatment within 
HIV services will prove to be an effective and cost-effective approach68,69.  
 
HCV elimination among HIV-infected MSM in the real world: Dutch experience  
 
In the Netherlands, surveillance data indicates that among PLWH, the vast majority of acute 
HCV infection diagnoses occur among MSM70. In this section, we detail the Dutch 
experience of HCV direct-acting antiviral (DAA) scale-up and impact on acute HCV incidence 
and HCV prevalence among HIV+ MSM. 
 
HIV and HCV care is well-organized in the Netherlands. All patients diagnosed with HIV are 
cared for by a team of infectious diseases physicians and specially trained HIV nurses in 26 
treatment centers spread across the country. Screening for chronic HCV is universal at 
entry into HIV care and more than 99% of the HIV infected patients in care in the 
Netherlands have been tested for HCV at least once71. Screening for incident HCV infections 
in MSM is performed by testing ALT (followed by HCV testing when a new ALT elevation is 
observed) twice a year. HCV/HIV coinfected MSM visit the HIV outpatient clinic at least 
twice a year. HCV infections can be treated by the infectious diseases physician so no 
referral to a hepatologist is needed. Facilitated by specially trained on-site data collectors, 
detailed clinical and laboratory data from consenting patients (98%) are registered in a 
central database, comprising the AIDS Therapy Evaluation in the Netherlands (ATHENA) 
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cohort. Additionally, two prospective acute HCV treatment studies among HIV+ individuals 
have occurred (Dutch Acute HCV in HIV Studies, DAHHS1 [from 2013-2014] and DAHHS2 
[2016-ongoing]) 72,73 in 17 centers providing care for 75% of the Dutch HIV+ MSM 
population. 
 
In the Netherlands, DAAs were available from September 2014 for HCV infected patients 
with significant liver fibrosis or cirrhosis, and October 2015 regardless of fibrosis stage. This 
led to a very rapid uptake of HCV therapy among HIV+ MSM in the ATHENA cohort, with 
79% attaining SVR just 14 months after restrictions were lifted74 and a substantial decrease 
in the pool of HCV RNA positive HIV infected MSM in care in the Netherlands. Indeed, while 
in 2015 4.1% (450 of 11070) of the HIV+ MSM in care were HCV RNA+, this decreased to 
1.5% (176 of 11749) by the end of 2016. As of May 2017, less than 150 HCV infected HIV+ 
MSM remain to be treated. With only 1.5% of the HIV+ MSM population currently 
remaining HCV infected, HCV elimination may become a reality. However the residual 
group of infected patients is likely a more difficult to reach subgroup, and the risk of 
reinfection among HIV-positive MSM is high33,34,75,76.  
 
The data described above demonstrate that a very rapid decline in the prevalence of HCV 
can be achieved in a well-organized health care system of a resource rich country. 
However, to achieve HCV elimination according to the WHO targets, the incidence of new 
HCV infections needs to decrease by 90% by 20302. We obtained data from the DAHHS 
studies to compare the incidence of acute HCV infections in the first year after universal 
DAA availability (2016) with the last year before DAA became available (2014). From 2014 
to 2016, a 51% decrease in acute HCV infections was observed77. Furthermore, this 
decrease contrasted with a significant increase in the percentage of positive syphilis 
(+2.2%) and gonorrhea (+2.85%) tests in HIV-positive MSM observed at STD clinics across 
the country78-80, indicating that the reduction in HCV was unlikely to be due to behavioral 
risk reduction. 
 
While the substantial reduction in HCV incidence among HIV+ MSM observed after 
widespread scale-up of HCV treatment in the Netherlands is reason for optimism, an 
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observational study cannot prove a causal relationship. Further modeling work will be 
required to disentangle the estimated impact of HCV treatment as prevention initiatives 
among HIV+ MSM in the Netherlands, and coverage required for elimination. We consider 
it unlikely that HCV treatment as prevention alone will result in a 90% reduction in the 
incidence of HCV (the WHO target) among HIV+ MSM in the Netherlands, and discuss 
additional steps likely required in the following section. Indeed, no further decline in the 
HCV incidence has been observed in 2017 so far81. Additionally, we note that the Dutch 
experience is a specific example within a resource-rich country with well-coordinated HIV 
and HCV care. Whether the experience in the Netherlands will translate to other resource 
limited settings requires further study.  
 
Probable and possible components required to achieve HCV elimination among PLWH  
 
In summary, despite the promise of HCV elimination using HCV treatment as prevention 
from both theoretical modeling studies and real-world observations in the Netherlands, 
numerous probable and possible barriers exist which could hamper HCV elimination efforts 
among PLWH (Table 2). As such, the following components are likely an important part of 
the HCV elimination response among PWLH (based on probable barriers):   
 
1. Regular HCV testing of high risk populations, both HIV+ and HIV-:  Among HIV+ PWID, 
modeling indicates that elimination likely requires elimination efforts among the 
broader PWID population25, yet worldwide an estimated 80% of HCV-infected 
individuals remain undiagnosed62, a situation which may be worse among PWID. For 
example, in India only an estimated 5% of HCV-infected PWID are diagnosed82. 
Consequently the treatment scale-up required for elimination among PWID likely 
requires enhanced testing among both HIV+ and HIV- PWID 22. Among HIV+ MSM, 
modeling indicates that regular testing of HIV+ MSM is also likely required for 
elimination. Testing of other MSM populations is described below under possible 
barriers.   
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2. Development of low cost, simple, reliable and accurate HCV diagnostics. Even in low-
income countries with low cost DAAs, the price of HCV diagnostics remain a barrier65.  
Additionally, the currently available diagnostic products are complex, many which 
require a cold chain and/or show poor accuracy among HIV-infected individuals83.   
 
3. Reduced costs for DAA treatment. Despite the availability of generic and low-cost 
DAAs in some resource limited settings, costs of DAA therapy in the vast majority of 
countries remains a barrier to widespread scale-up of HCV treatment57,84,85. Greater 
market transparency and price negotiations are required84.  
4. Broad access to HCV treatment without restrictions: Modeling studies indicate that 
restricting treatment for those with more advanced fibrosis and/or by drug use status, 
as is occurring in many settings58,59, will likely have limited impact on preventing 
transmission among PWID populations86, the vast majority who are younger with less 
advanced disease. In settings where HCV epidemics are predominantly PWID-driven, 
broad access to HCV treatment regardless of disease stage is therefore required for 
HCV elimination. Even in settings with substantial general population transmission, it 
is likely that restricting treatment for more advanced disease stages will mean that 
substantially more treatments are required to achieve elimination87. 
 
5. Close monitoring for reinfection and retreatment of reinfections: Treating those at risk 
of transmission, the target group for HCV treatment as prevention efforts, will result 
in reinfections. Among PWID, lower rates of reinfection compared to primary infection 
were reported in the IFN-era88, and reinfection rates among PWID on OST in DAA trials 
have been low (<3 per 100 person-years)89. However, modeling in a rural expanding 
epidemic setting in the United States indicates achieving the WHO elimination 
incidence target among PWID requires retreatment of reinfections21. Among HIV+ 
MSM, European studies indicate high incidence of HCV reinfection in HIV+ MSM (2-10 
fold that of primary infection rates) in both the IFN-era 33,34,76 and DAA era 75. As 
modeling studies have shown that more frequent testing for HCV and earlier initiation 
of HCV treatment could reduce the HCV epidemic among HIV-positive MSM 31,90 and 
given that those previously infected with HCV are a particularly high risk sub-
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population for transmission, reducing the time from reinfection to retreatment is 
important. This could be achieved by increasing the frequency of HCV reinfection 
screening and may require out of the box diagnostic strategies like a home-based 
diagnostic approach in which the patient collects dried blot spots that are sent to the 
lab for HCV RNA or antigen testing.  
 
6. Harm reduction and other behavioral interventions to prevent infection/reinfection: 
Despite the importance of harm reduction such as opiate substitution therapy and 
needle and syringe programs for preventing HCV infection among PWID9, access to 
these interventions in many settings is poor, particularly in many resource limited 
settings91. Scale-up of harm reduction, as recommended by the WHO2, is crucial. 
Additionally, among HIV+ MSM, effective behavioral interventions to prevent HCV 
infection are urgently required, as modeling from several settings indicates 
elimination of HCV in this population without effective behavioral intervention will be 
unlikely29,31,92. Unfortunately, there is a lack of robust evidence surrounding the 
efficacy of behavioral change interventions targeting HCV risk among HIV+ MSM. It is 
possible that some interventions developed to prevent HIV transmission among MSM 
may also be effective against HCV, particularly those targeting unprotected anal 
intercourse29,93. There is an emerging body of literature examining the development 
of educational and counseling interventions targeted at MSM who engage in 
ChemSex94-96, which may reduce the risk of acquiring HCV among this population. 
Further research is needed examining the development, acceptability, and efficacy of 
culturally sensitive behavioral change interventions for preventing HCV infection. 
 
Additionally, the following items would address possible barriers to elimination and 
therefore may be required for elimination among PWLH. We note that further evidence is 
required to support whether these items are necessary components of an elimination 
response:   
 
1. Testing among HIV-negative MSM receiving HIV pre-exposure prophylaxis (PrEP): 
There is growing evidence of HCV infection among HIV-negative MSM receiving PrEP, 
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a group which could contribute to HCV transmission to HIV+ MSM. In Amsterdam, the 
prevalence of chronic HCV among HIV-negative MSM in a PrEP implementation 
program was 4% (15/375), comparable to the prevalence of 4.2% in HIV+ MSM97. In 
Antwerp, Belgium, HCV prevalence among HIV-negative MSM at the start of a PrEP 
project was 2%, and several new HCV infections were diagnosed during follow-up in 
these PrEP users (B Rijnders, personal communication). The extent to which HIV-
negative MSM (particularly on PrEP) contribute or will contribute to the HCV epidemic 
among HIV+ MSM in unclear, but increased epidemiological surveillance will shed light 
on the burden of disease in this group and help understand their potential importance 
to the HIV+ MSM epidemic.  
 
2. Coordinated multi-country prevention and treatment effort: Among HIV+ PWID, the 
contribution of cross-border transmission and import/export of infections to the 
epidemic is unclear. Among HIV+ MSM,  the highly connected nature of the HCV 
epidemic among HIV+ MSM in Western Europe and frequent travel of MSM between 
European cities has been documented98,99. Therefore, at least in Europe, local 
elimination of HCV among HIV+ MSM may require coordinated multi-country efforts.  
 
3. Licensing for treatment in the acute stage: Currently none of the approved DAA 
regimens are licensed for the treatment of acute HCV. Depending on the regional 
legislations, this may result in a compulsory "wait for documented chronicity" policy 
and thus increase the duration of time for onwards HCV transmissions to occur. HIV 
modeling studies have highlighted the importance of the acute HIV stage on the HIV 
epidemic100. However, the importance of acute HCV infection in relation to the HCV 
epidemic among PLWH is unclear and further research is needed to determine to 
what degree and in what populations early treatment is required for achieving 
elimination targets. 
 
4. Monitor if transmission of HCV clones with acquired DAA resistance occurs: It was 
recently shown that the HCV Q80K polymorphism, associated with DAA resistance, is 
frequently detected and transmitted among HIV+ MSM in the Netherlands 101. As 
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relapse with documented DAA resistance is rare, the chance of a patient developing 
ánd transmitting acquired DAA resistance is theoretically small and as far as we know 
has only been described in the context of treatment with a first generation protease 
inhibitor102. As such, further research is needed to ascertain the importance of 
resistance in the DAA era. 
 
Conclusions           
 
Both theoretical modeling studies and emerging real world evidence from the Netherlands 
indicate that HCV elimination among HIV-infected key populations such as MSM and PWID 
is potentially achievable.  
 
Due to a number of factors, elimination of HCV among HIV+ MSM may be complex; and 
require both high coverage HCV treatment and behavioral interventions. Elimination 
among HIV+ PWID will likely require elimination efforts among PWID more broadly. In 
addition to HCV treatment as prevention initiatives, elimination among PLWH also likely 
requires regular HCV testing, development of low-cost accurate HCV diagnostics, reduced 
costs of DAA therapy, broad treatment access without restrictions, close monitoring for 
HCV reinfection and retreatment, and harm reduction and/or behavioral interventions. 
Finally, we note that the vast majority of existing research is limited to high income 
settings, and more research is required relating to HCV elimination among PLWH in 
resource limited settings. For example, more modeling work is needed to assess what 
scale-up is required for HCV elimination among PLWH populations in resource-limited 
settings where transmission routes may vary and the HCV epidemics among HIV-infected 
populations may differ. Many developing countries have high burdens of injecting drug use 
as well as high HCV among HIV-infected PWID10,103. Yet, their risks may be different from 
high income settings. For example, an increasing number of analyses are focusing on HCV 
elimination among the general population in low or middle-income country settings such as 
Georgia and Pakistan87,104, which have shown that even in settings with high numbers of 
PWID, transmission may be highly disseminated, with PWID experiencing risk both from 
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injecting drug use and the broader community through iatrogenic transmission. Hence, the 
requirements for elimination in these settings where PWID experience multiple risks may 
be different than in other settings.  
 
Additionally, data are lacking on HCV among MSM in resource-limited settings, and as such 
the magnitude of the problem and requirements for elimination are unclear. In addition to 
differences in epidemic characteristics, clearly economic considerations across resource-
limited countries will vary substantially, and as such the requirements for achieving HCV 
elimination among PWLH in these resource limited settings requires further study. 
 
 
 
 
Table 2 Barriers to HCV elimination among PLWH 
 
Probable barriers to HCV elimination among PLWH: 
 Low levels of diagnosis in many settings and risk populations62 
 Lack of availability of low cost, simple, reliable, and accurate HCV diagnostics for 
LMIC settings65,83 
 High costs of DAA treatment57 
 Restrictions on DAA accessibility by fibrosis stage and drug use status58,59 
 Low levels of harm reduction availability for PWID in many settings91 
 High reinfection incidence among HIV+ MSM33,34,75,76 
 Lack of evidence-based interventions to reduce HCV infection among HIV+ MSM 
Possible additional barriers: 
 Transmission of HCV from HIV uninfected MSM, such as those on PrEP 
 Spread of HCV clones with acquired DAA resistance101 
 Lack of licensing for HCV treatment in the acute stage 
 Cross border transmission of HCV, particularly among HIV+ MSM98,99 and between 
countries with different levels of DAA availability 
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Part A: Optimization of hepatitis C therapy in the era of DAA   
 
The advent of direct-acting antivirals (DAA), with cure rates of the most recent regimens up 
to 95% and higher, has changed the field of hepatitis C virus (HCV) infection. HCV infection 
has now become a curable disease for almost all patients. In part A of this thesis concerns 
the optimization of HCV therapy  in the era of DAA as therapy shortening can be a strategy 
to reduce costs and improve adherence.  
 
HepNed-001 study 
The first clinical trial of this thesis looked at the efficacy of 8 weeks of ledipasvir/sofosbuvir 
(LDP/SOF) in non-cirrhotic patients infected with HCV genotype 4 (Chapter 2). With this 
shortened regimen, 37 of 39 patients of the on-treatment population were successfully 
treated for the HCV present at baseline (95%; 95% C.I. 83-99%). Although the study was 
limited to 44 patients only and therefore precluded the conclusion of statistical non-
inferiority compared to a conservative fixed 95% success rate (deducted from earlier HCV 
genotype 4 treatment studies1,2), this outcome remains very relevant.  
First, the initial phase 2 study and the study which led to the FDA- and EMA-approval of 
LDP/SOF for HCV genotype 4 infections included respectively 21 and 44 patients, which 
gives an indication about the obtainable sample sizes in the field of DAA research for HCV 
genotype 4. In the NIAID Synergy trial1 and the 1119 study2, respectively 20 out of 21 
patients (95%; 95% C.I. 76-100%) and 41 out of 44 patients (93%; 95% C.I. 81-99%) with 
HCV genotype 4 infection were successfully treated with 12 weeks of LDP/SOF. Second, 
HCV genotype 4 infections are more frequently seen in low and middle income countries3, 
but large therapeutic clinical trials used to focus on genotype 1 HCV mono-infections in 
high income countries4. Being able to shorten treatment for HCV genotype 4 could improve 
the access to therapy, especially in countries with a high prevalence of HCV genotype 4 and 
in which the costs of therapy limits its use. In fact, in 2015, prices for 12 weeks of LDP/SOF 
were considered as globally unaffordable and a threat to the sustainability of health care 
systems in many countries, preventing large-scale provision of treatment5. Even in 2017, 16 
European countries still had restrictions for DAA therapy in place, which was not consistent 
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with the EASL guidelines for HCV treatment applied at the time and probably driven by 
economic choices6. Third, this clinical trial confirms the results reported by Shiha et al. who 
studied the efficacy of 8 weeks LDP/SOF in Egyptian HCV genotype 4 non-cirrhotic mono-
infected patients of whom 41 of 44 patients were successfully treated (SVR12 95%; 95% C.I. 
84-99%)7. Different from this Egyptian study, the HEPNED-001 study was the first to 
examine the efficacy of an 8-week regimen in patients with HCV genotype 4 regardless of 
their HIV status.   
In addition to the difference in HIV-status compared to the study by Shiha et al., Dutch and 
Belgian HCV genotype 4 subtypes are different from the subtypes found in Egyptian 
genotype 4 patients. In Dutch genotype 4 patients, the (former) HCV epidemic among 
PWID and the current HCV epidemic in MSM consists mostly of HCV genotype 4d 
infections8, but the Egyptian nosocomial epidemic consists mostly of HCV genotype 4a 
infections9. Although it has become clear that for the genotype 1 subtypes 1a and 1b 
treatment response can be different, this was initially less clear for the genotype 4 subtypes 
given the small number of HCV genotype 4 patients in clinical trials. However, recent 
studies seem to indicate that also for HCV genotype 4 not all subtypes seem to have the 
susceptibility for DAA therapy.  
In the 1119-study, discussed earlier in this paragraph, SVR12 rates after 12 weeks of 
LDP/SOF were 100% for al subtypes except for genotype 4b (1 patient with the double 
NS5A RAS L28M + L31M) and 4r (2 patients with both L28M/V + L30R + L31M). However, all 
patients (n=44) had at least one baseline NS5A RAS, 21 patients had 2 NS5A RAS and 6 
patients had 3 NS5A RAS, making the clinical interpretation difficult2,10. On the other hand, 
a French study which included 121 genotype 4 patients with virological failure after DAA 
treatment saw an over-representation of genotype 4r patients (n=27; 22%) compared to 
the prevalence in the general French population11 and a Rwandan clinical trial found that 
after treatment with 12 weeks of ledipasvir/sofosbuvir only 54% of genotype 4r reached 
SVR12 compared to 87-100% for the other genotype 4 subtypes12. Furthermore, Welzel et 
al. analyzed 309 patients infected with HCV genotype 4 from several phase II/III DAA clinical 
trials13. The patients showed a wide range of HCV genotype 4 subtypes. Up to 11 different 
genotype 4 subtypes are circulating in Europe. This contrasts with HCV genotype 1 and 3, of 
whom mostly 1 or 2 subtypes circulate regionally. Interestingly, the level of baseline RAS 
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seemed to be subtype specific and especially genotype 4r harbored double or triple NS5A 
RAS at baseline. Reflecting the current African and Asian immigration to Europe, the 
proportion of patients with a non-4a/4d HCV may increase in the future14.  
In the HepNed-001 study, one of the patients with virological failure was infected with a 
HCV genotype 4c. In the other patient, an African migrant, the virus was non-typable but 
showed some similarities with both subtypes 4g and 4r. For future (research) purposes, it 
could be recommended to not only determine the HCV genotype with a reverse hybridizing 
assay (Versant® HCV Genotype 2.0 System; INNO-LiPA), but also determine the subtype in 
genotype 4 patients with for example NS5B sequencing13 to at least monitor the local 
prevalence of RAS and the prevalence of the more difficult to treat HCV genotype 4 
subtypes, like 4b and 4r.  
In conclusion, the HepNed-001 study showed that a shortened 8 week regimen of LPD/SOF 
for non-cirrhotic HCV genotype 4 infected patients with a HCV RNA load <10 million IU/ml 
led to sustained virological response in 95% patients. This knowledge may facilitate the 
reduction of therapy costs, one of the WHO’s priority actions regarding to the elimination 
of HCV infection as a public health by 2030. However, caution is advised with regard to 
non-4a/4d subtypes as discussed above. This stresses the importance of fully 
understanding the local HCV epidemic and tailoring interventions accordingly. 
 
DAHHS 2 study 
In the second clinical trial described in this thesis, concerns the efficacy of 8 weeks of 
grazoprevir/elbasvir (G/E) for the treatment of acute HCV infection (Chapter 3). In this 
multicenter single arm open label clinical trial, 79 out of 80 patients in the intention to treat 
population reached sustained virological response (99%; 95% C.I. 93-100%). Until recently, 
it was not known whether DAA treatment in the acute phase of HCV infection would be 
effective compared with their use for the treatment of chronic HCV infection. However, 
over the last few years the results of several studies on the use of DAA for the treatment of 
acute HCV infection became available. Nonetheless, they were all limited to small studies 
and most included only genotype 1 infected patients. This study is the first adequately 
powered clinical trial for the treatment of acute HCV infection with DAA to demonstrate 
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non-inferiority when compared to the cure rates observed with treatment of chronic HCV 
infection with the same regimen. The DAHHS 2 study proved that: 1) treatment of HCV 
infection with G/E in the acute phase is effective; 2) that the treatment duration can be 
shortened from 12-16 weeks to 8 weeks without loss of this effectiveness, and: 3) that in 
the Dutch setting of HIV-care treatment of acute HCV infection is feasible. The study in -and 
exclusion criteria required that patients initiated therapy within 26 weeks after infection 
and almost all patients could be treated within this timeframe. 
At this moment, more clinical trials on the use of DAA for the treatment of acute HCV 
infection are ongoing. For glecaprevir/pibrentasvir (G/P), two small arms are added to the 
target3D-study in which 2 groups of 30 participants will be treated with either 6 weeks or 4 
weeks of G/P (NCT02634008). And in the adequately powered REACT-study, 250 
participants will be randomized 1:1 to 6 or 12 weeks of sofosbuvir/velpativir (SOF/VEL) 
(NCT02625909). The advantage of these regimens is their pan-genotypic nature which 
could allow for immediate treatment without genotype testing if proven to be effective for 
acute HCV infection of the genotype 3, as in regions were acute HCV infection is more often 
diagnosed in people who inject drugs, genotype 3 needs to be taken into account as well.  
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Part B: Effect of DAA and PrEP on the HCV epidemic among MSM  
In part B of this thesis describes the effect of HCV direct-acting antivirals and HIV pre-
exposure prophylaxis on the HCV epidemic among HIV-positive men who have sex with 
men. It takes the effects of two other recent developments into account: the unrestricted 
availability of direct-acting antivirals for chronic HCV infection (Chapter 4 and 5) and the 
introduction of HIV pre-exposure prophylaxis for HIV-negative persons at risk (Chapter 6). 
But first, to fully appreciate the HCV epidemic among these patients, the HCV care 
continuum is visualized in a schematic way as an extension to the treatment cascade 
discussed in Chapter 4.  
Extension of the HCV ‘treatment cascade’ into a HCV ‘care continuum’ 
To define which interventions may have a profound impact on the continuum of HCV care 
in a specific country or for a specific key population, it is important to understand the HCV 
epidemic. For HIV care, treatment cascades are widely used and global treatment goals are 
monitored with it (like the UNAIDS 90-90-90 HIV treatment targets). The advantage of such 
a visualization of the local epidemic is that ‘gaps in care’ are seen at a glance, as for every 
next step in the cascade a proportion of patients will be lost (as described in Chapter 4). 
However, the treatment cascade described in Chapter 4 is merely a cross-sectional static 
representation of ‘known’ Dutch co-infected patients in care. To really understand and 
visualize the HCV epidemic among these patients one should look at the total HCV care 
continuum, which is more dynamic and also depends more on estimates than the 
treatment cascade (figure 1, next page). On left of the treatment cascade (in the dotted 
box) the following should be added: 1) the total population at risk for HCV infection and 2) 
the patients of whom the HCV status is unknown or patients who got lost to follow up 
(which together with the HCV/HIV-coinfected MSM tested and in care form an estimate for 
the ‘true prevalence’). Neither does the HCV care continuum end with ‘cure’ (sustained 
virological response) as reinfections are frequently observed in certain high risk 
populations, and in particular, in HIV-positive MSM in the Netherlands15,16. Several aspects 
of the HCV care continuum will be discussed in greater detail in the next paragraphs with a 
specific focus on the impact of highly effective DAA.  
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Figure 1. Schematic representation of the HCV continuum of care in Dutch HIV-positive MSM.  
 
This continuum of care is depicted as an extended version of the treatment cascade discussed in 
Chapter 4 (in dotted box) as described on page 149. Possible barriers (in red) and strategies (in 
green) for HCV elimination among this key population are depicted around the HCV continuum of 
care and will be discussed separately throughout the summarizing discussion (this Chapter). 
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The effect of DAA on the HCV epidemic among Dutch HIV-positive MSM 
1. The effect of unrestricted availability of DAA on the HCV prevalence  
In Chapter 4 of this thesis describes the treatment cascade of the national HCV epidemic in 
HIV-positive patients up until February 2017 using data from the Dutch ATHENA cohort. 
This cohort captures data on 98% of patients with HIV in care in the Netherlands and is 
therefore highly representative of the overall Dutch HIV/HCV epidemic. The treatment 
uptake and treatment success of direct-acting antiviral therapy was investigated in the 
Dutch HIV-positive population shortly after the introduction and reimbursement of HCV 
direct-antiviral therapy. It showed that as of February 1st 2017, 76% of the Dutch HIV/HCV-
coinfected patients in care had been successfully treated for HCV infection. A recent 
updated analysis of the cohort up until the 1ste of January 2018 showed that the number 
successfully patients increased to 83%17. Shortly after the study each HIV treatment center 
was provided with a coded list of patients remaining in need of curative HCV treatment in 
order to facilitate the identification and re-evaluation of these patients.  
Treatment uptake and HCV cure rates were highest in MSM and significantly higher than in 
other categories of co-infected patients. Lifting the reimbursement restrictions, making 
DAA available for all patients regardless of fibrosis stage was followed by a major decline in 
HCV prevalence in HIV-positive MSM. However, practitioners should keep in mind that 
other HCV-infected populations, like PWID, non-Dutch patients and females, as described in 
Chapter 4, may need more support to (re-)start DAA therapy or during HCV therapy in 
order to avoid disparities in the national HCV treatment cascade.  
2. The effect of unrestricted availability of DAA on the HCV incidence  
Besides looking at the prevalence of chronic HCV infections among HIV-positive MSM, the 
incidence of HCV infections is of equal interest. In fact, one of the WHO’s impact targets is a 
90% reduction of new HCV cases by 2030. It is promising that treatment uptake is high 
among Dutch HIV-positive MSM which may favorably contribute to reduce ongoing HCV 
transmission in the Netherlands by interruption MSM-specific transmission networks18-21. 
Chapter 5 investigates the acute HCV incidence among Dutch HIV-positive men who have 
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sex with men before and after direct-acting antiviral therapies became available without 
restrictions in 2015. In 2016, there was a 51% decrease in acute HCV infections among 
Dutch HIV-positive MSM compared to 2014. This study was the first to describe empirical 
data in support of what recent modeling studies had predicted; universal HCV therapy for 
all HIV-positive MSM chronically infected with HCV will result in a decrease in the number 
of acute HCV infections in this population22-24. The high treatment uptake among Dutch 
HIV-positive MSM is the most likely explanation for the prompt decrease in HCV incidence 
among Dutch HIV-positive MSM, as high risk behavior is likely to be continued after HCV 
diagnosis, indicated by the high rate of STD’s during this clinical trial and reported 
nationally for 2014 as well for 2016 by the RIVM.  
However, this HCV treatment as prevention effect seen among Dutch HIV-positive MSM 
probably cannot be extrapolated to other key populations or even to other HCV epidemics 
among HIV-positive MSM due to different local settings. The type and extent of therapeutic 
interventions needed among HIV-positive MSM to reach the WHO’s 2030 elimination 
targets seems to be dependent on the incidence trends and the local epidemical 
background (Chapter 7). Martin et al. showed that for the UK, with a stable HCV incidence 
(comparable to the situation within the Netherland before unrestricted access to DAA 
therapy), the elimination targets could be reached when treating all patients within 1 year 
after diagnosis or combining treatment scale up with behavioral risk reduction25. However, 
in the setting of increasing HCV incidences like observed in Switzerland and Berlin, 
modeling studies showed that despite treatment scale up the targets would not be reached 
and other intervention, like reduction in high-risk behavior, are definitely needed23,26. 
Moreover, Pradat et al. reported recently on an increasing primary HCV incidence in French 
HIV-positive MSM despite a high DAA uptake among the same high risk group27. Probably, 
the stable incidence rates and the very rapid DAA treatment uptake immediately after the 
lifted restriction criteria among Dutch HIV-positive MSM have been favorable factors the 
led to the incidence decline described in Chapter 5. However, Salazar-Vizcaya et al. 
predicted that although an intensive intervention (1 year of early DAA therapy combined 
with behavioral counseling) could lower the incidence over the intervention period, the 
benefit would disappear again over time after stopping the intervention28, emphasizing the 
importance of continued efforts to tackle the epidemic. 
Summarizing discussion and future perspectives 
153 
 
8 
3. The effect of DAA treatment for the acute phase of HCV infection 
As stated for the HepNed-001 study (Chapter 2), shortening of therapy leads to a reduction 
of costs, which then could improve access to therapy. But when combining therapy 
shortening with treatment in the acute phase of HCV infection (Chapter 3), this could lead 
to a second and maybe equally important advantage in combating the HCV epidemic in 
high risk patients: treatment as prevention. Waiting for spontaneous clearance to avoid 
over-treatment of an infection seems sensible. Actually, the burden of disease after HCV 
acquisition only becomes apparent decades after infection and only in a subset of patients. 
Furthermore, treatment is expensive. However, when looking from a public health 
perspective, decreasing the time that a patient remains infectious after HCV acquisition and 
therefore treating patients as soon as possible after diagnosis makes sense as well: 
prevention of new infections in others could be an additional benefit of treatment of acute 
HCV infection. Moreover, ‘HCV treatment as prevention (TasP)’ could be even more 
effective than ‘HIV TasP’29, because HCV treatment has to be administered for months 
rather than a lifetime as in the case of HIV infection.  
The current European guidelines on HCV treatment (EASL Recommendations on Treatment 
of Hepatitis C 201830 and European Guidelines for treatment of HIV-positive adults in 
Europe 2018 version 9.131 already advocate treatment of acute HCV infection ‘without 
delay’ and ‘at diagnosis’ if there is a high risk of onward transmission. However, these 
recommendations are based on expert-opinion, as at the time of writing of these 
guidelines, the ideal time point for starting treatment was not well-established and the 
impact on the epidemic and the cost-effectiveness of these interventions were largely 
unknown. Recently, two studies on the cost-effectiveness of immediate DAA therapy 
showed that this strategy could be cost-saving in the setting of risk of onwards transmission 
of HCV to others. Moreover, one of these studies was modelled in the setting of Dutch HIV-
positive MSM. 
Bethea et al. predicted that in the setting of patients at risk of transmitting HCV in the 
population with acute HCV infections in the United States, a shorted treatment of 6 instead 
of 8 weeks of LDP/SOF could be cost-saving32. For the Dutch situation, Popping et al. 
predicted that immediate DAA treatment at the cost of 35.000 euro per patient would both 
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lower the prevalence and incidence of HCV in HIV-positive MSM over the course of 40 
years and that this strategy would be the most cost-saving, compared to waiting for 
spontaneous clearance (waiting 6 months until HCV infection becomes chronic) or 
deferring treatment to F2 stage fibrosis33. Sensitivity analysis showed that immediate 
treatment remained cost-saving, despite the fact that varying the DAA price between 
5.000-50.000 euro had a substantial impact on the exact incremental cost-effectiveness 
ratio’s (ICER). In the study, the authors did not take into account that in the setting of 
immediate treatment, treatment durations can be shortened compared to treatment of 
HCV in the chronic phase to save costs. However, at the time that the study by Popping et 
al. was performed, the exact costs of DAA therapy in the Netherlands were unknown as a 
result of price negotiations between companies and the ministry of health which remained 
undisclosed. However, in 2019 these negotiated deals came to an end and the acquisition 
costs of each of the DAA is now publicly available (table 1).  
 
 
 
Table 1. Price of DAA combinations in the Netherlands. 
  Regimen   Price for 12 weeks of treatment (€)* 
  Sofosbuvir   29.250 
  Ledipasvir/sofosbuvir   37.125 
  Paritaprevir/Ritonavir/Ombitasvir +/- Dasabuvir   35.408 +/- 3.152  
  Grazoprevir/Elbasvir   21.000 
  Glecaprevir/Pibrentasvir    36.000 
  Velpatasvir/Sofosbuvir   24.750 
  Velpatasvir/Sofosbuvir/Voxilaprevir   42.000 
 
 
*Price in euro’s for 12 weeks of treatment according to ‘HCV richtsnoer’ version 10 March 2019. 
Accessed at 17-04-2019, www.hcvrichtsnoer.nl.  
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In summary, treatment of acute HCV infection with 8 weeks of G/E is a plausible strategy to 
bring us closer to the WHO 2030 elimination goals, at least in the setting of HIV-positive 
MSM. Immediate DAA therapy should be incorporated into Dutch treatment guidelines for 
Dutch HIV-positive MSM. It’s effectivity in the acute phase of HCV infection has now been 
proven and the intervention is not only cost-effective but can even lead to costs saved if a 
shortened treatment duration can be prescribed as demonstrated in the DAHHS2 study. 
Furthermore, declining treatment for acute HCV infection in high risk patients because of 
the fear of swift reinfection can lead to stigma. This should be avoided at all costs to assure 
equal access to testing services and therapy.   
Studies must be done in order to examine the feasibility of acute HCV therapy in other 
settings and for other DAA regimens. A major limitation for this treatment strategy is that, 
as acute HCV infection often is a subclinical disease, patients must be in a system where 
they can be frequently monitored for new HCV infections. For Dutch HIV-positive MSM, of 
whom most are in care and visit the HIV outpatient clinic regularly, this should not be a 
problem. However, this strategy might not be easily extrapolated to other settings in which 
monitoring of new infections and follow up of patients can be more chaotic (e.g. in PWID). 
 
HCV infection among HIV-negative MSM in the PrEP era 
Chapter 6 describes 10 cases of newly acquired HCV infections in Dutch and Belgian HIV-
uninfected MSM that were encountered during the DAHHS 2 study. This case series 
illustrates that, even without an active HCV screening policy for HIV-negative MSM, acute 
HCV infections are diagnosed within this group. Until recently, sexually acquired HCV 
infections were regarded as limited to HIV-positive MSM as several cohort studies showed 
a low prevalence in HIV-negative MSM34-36. However, this case series shows that at least a 
subgroup of HIV-negative MSM are at increased risk and touches upon an important point 
in the discussion about HCV elimination in MSM: HIV pre-exposure prophylaxis (PrEP). In 
this case series, 5 out of the 10 patients were using PrEP and 1 patient used post-exposure 
prophylaxis on a very regular basis. Furthermore, all patients reported unprotected anal 
intercourse and most reported the use of oral drugs to increase sexual pleasure during 
intercourse (Chemsex). Therefore, the patients from this case series whom were not on 
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PrEP would actually have been good candidates to be prescribed PrEP and can be expected 
to start using PrEP as soon as it becomes available in the Netherlands. These results 
contrast with a recent study on the prevalence of anti-HCV antibodies at a large STI clinic in 
Amsterdam37. During October 2016 the anti-HCV prevalence among HIV-negative MSM was 
1.0% as out of 504 HIV-negative MSM only 5 were anti-HCV positive and all were HCV RNA 
negative. The authors concluded that the HCV prevalence among HIV-negative MSM 
remained stable compared to previous years. However, this might not be true for the 
subgroup of HIV-negative MSM with the highest risk behavior. At the time of this HCV study 
at the STI clinic the AmPrEP study was already ongoing. In this PrEP demonstration project 
MSM receive PrEP and 3-monthly STI screening. Therefore, these “high-risk” MSM from 
Amsterdam were very likely to no longer attend the STI clinic. The HCV prevalence in these 
375 PrEP-using MSM was 4.8% (95% C.I. 2.9-7.55)38. In another PrEP study, the London 
PROUD study, the analysis of the deferral arm showed that the study attracted population 
with higher STI rates than the general MSM population attending sexual health clinics in 
England39. These observations clearly illustrate that in specific MSM subgroups, like PrEP 
users, HCV monitoring is crucial. If other subgroups of MSM (e.g. MSM diagnosed with a 
STI) need to be monitored for HCV infection remains to be defined.  
During the first PrEP clinical trials, the iPrEx and the PROUD study for continuous PrEP40,41 
and the ANRS IPERGAY trial analysis on demand PrEP42, no compensatory increased sexual 
risk behavior was observed in MSM using PrEP. However, in the subsequent open-label 
phase of the ANRS IPERGAY trial, a significant decrease in condom use was seen43. 
Furthermore, among 220 MSM attending a sexual health clinic in Seattle and starting PrEP 
between 2014-2016, a decreased in condom use was reported as well44. These results were 
confirmed by recent results of the Dutch AmPrEP study as during the first 6 months after 
initiation of PrEP a significant increase in unprotected anal intercourse was observed45. The 
observations described above and the fact the use of PrEP may also reduce HIV-serosorting 
(the preferential selection of sex-partners with the same HIV serostatus) in the MSM 
community raises the question if the HCV prevalence in HIV-uninfected MSM will increase 
in the future as well. If so, could this hamper the future elimination of HCV among all 
MSM?  
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Several studies have already shown that sexual HCV transmission networks between HIV-
positive and HIV-negative MSM are overlapping. In France, the HCV strains of 6 HIV-
negative MSM (of whom 4 used PrEP) were included in different clusters of HCV-infected 
HIV-positive MSM46. In the Netherlands, 13 out of the 15 HIV-negative MSM with HCV RNA 
positivity in the AmPrEP study were part of 6 HIV-positive MSM-specific clusters. Thus the 
spread of HCV between HIV-negative and HIV-positive MSM is possible. However, studies 
have shown that HIV-negative patients do have a higher rate of spontaneous clearance. 
Thus as a larger part of these patients will not develop chronic disease and they have a 
considerably shorter period of being infectious to others, compared to HIV-positive MSM, 
the force of infection for this HIV-negative subgroup will be much lower. To date it is not 
clear whether transmission of HCV to HIV-negative MSM will hamper the future elimination 
of HCV in both HIV-negative and HIV-positive MSM.     
However, as the care for HIV-negative MSM is divided between multiple care givers, like 
general practitioner and sexual health clinics, PrEP and STD tests can be easily ordered 
without medical surveillance (e.g. ordered online) and the number of HIV-negative MSM at 
risk is not clear, surveillance of the HCV incidence and prevalence may become very difficult 
within the next few years. Furthermore, monitoring the incidence of HCV among risk-
groups is difficult and can at times be unreliable was recently illustrated in a study on the 
incidence of acute HCV among HIV-positive MSM in the Netherlands. In this study, incident 
acute HCV infections were prospectively registered in 19 HIV clinics spread across the 
Netherlands47. This observed number was much higher compared to the national number 
of acute HCV infections reported by the RIVM48, despite the fact that it is obligatory to 
report an acute HCV infection. To prevent this from happening for HIV-negative MSM, 
different stake holders (general practitioners, sexual health clinics, hepatologists, 
infectiologists, etc.) have to cooperate. At least nationwide surveillance, specifically 
designed to monitor acute HCV infections, should be in place to keep track of the periodic 
HCV incidence among this risk group. This is currently not the case because STD clinics in 
the Netherlands do not test HIV-negative MSM for HCV infection in a systematic way and a 
system to periodically monitor HIV-negative MSM is not in place. With the expected roll-out 
of PrEP at GGD clinics across the Netherlands, monitoring for HCV infection among HIV-
negative PrEP users should become feasible on short notice.  
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Part C: Is micro-elimination of HCV in Dutch HIV-positive MSM possible? 
Final summary and implications for future research 
 
The overall aim of this thesis was to investigate and discuss possible barriers and strategies 
for micro-elimination of HCV infection among Dutch HIV-positive MSM in the era of DAA.  
In order to be able to eliminate an infectious disease, the following biological criteria need 
to be present: 1) the availability of an effective intervention and the possibility to 
implement it; 2) the availability of a diagnostic tool with sufficient sensitivity and specificity, 
and; 3) humans are essential for the life cycle of the agent and the only reservoir for the 
infectious disease49. And, in fact, only two actions are needed to eliminate an infectious 
disease: existing infections must be found and cured (lowering the prevalence, chapter 4); 
plus new infections must be prevented (lowering the incidence; chapter 5). However, the 
path towards elimination consist of many small intertwined steps as will be discussed in this 
final part. Moreover, the financial, social and political commitment to (future) elimination 
plans play a big role49. Fortunately, the WHO has created this commitment by releasing the 
2030 elimination goals for viral hepatitis. As discussed in the introduction (Chapter 1), one 
of these WHO’s 2030 elimination goals consists of a 90% drop in HCV incidence to establish 
elimination of HCV as a public health threat and to reassure ‘control’ of the HCV epidemic 
at locally acceptable level49,50. The WHO stated that the continuum of HCV care should be 
tailored to the specific epidemic within a population or setting to curb the epidemic in 
order to reach these elimination goals. Micro-elimination, which can be defined as 
‘reaching the WHO 2030 targets within a local well-defined key population’, is often 
regarded as more feasible than national or global elimination as specific interventions can 
be implemented faster and more efficiently within a specific key population51.  
This thesis specifically looks at interventions regarding the HCV epidemic among HIV-
positive MSM as they are a well-defined population in the Netherlands. Although it will 
never be possible to discuss all the factors influencing an epidemic, this last paragraph 
sums up the most relevant factors contributing to or hampering the WHO’s 2030 
elimination goals for HCV infection among Dutch HIV-positive MSM (Figure 1, page 151) 
and assess the implications for future research. 
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Barriers that could hamper the WHO elimination goals among Dutch HIV-positive MSM  
 
1. Interaction with HCV-infected HIV-negative MSM, as describe in more detail in Chapter 
6 and this previous paragraph of this summarizing discussion, could hamper the 
elimination of HCV infection among both HIV-negative and HIV-positive MSM. Ideally, a 
nationwide database, with a known total number HIV-negative MSM (denominator), 
should be in place to precisely monitor the HCV incidence within this subgroup. At this 
moment, a database of HCV-monoinfected patients is being developed52. Furthermore, 
in the near future an large epidemiological study will be executed across STD clinics in 
the Netherlands and Belgium to give a reliable estimate of the HCV prevalence among 
HIV-negative MSM.  
 
2. As the Dutch MSM network is not a closed system, interaction with non-Dutch HCV-
infected MSM within global transmission networks could hamper the elimination of 
HCV. In 2009, van de Laar et al. revealed a large international network of HCV 
transmission among HIV-positive MSM with phylogenetic analysis20. However, a recent 
study showed that for the Swiss situation, although both international and domestic 
HCV transmission have played major roles in their epidemic between 2000 and 2007, 
local HCV transmission among HIV-positive MSM was the main source of infection 
between 2008 and 201621. Future studies should access to which extent global and 
European interaction between MSM could influence the local Dutch HCV epidemic. And 
if so, efforts should be made to eliminate HCV among HIV-positive MSM on an 
European and maybe even global level.  
 
3. Recently, 4 local retrieval projects for once HCV-positive patients whom are lost to 
follow up were executed52. For Dutch HIV-positive MSM re-identification seems less 
relevant, as there are regarded as a subgroup with a high linkage to care and with a 
small proportion of undiagnosed patients. Kracht et al. found that after analyzing 269 
‘lost to follow-up’-patients with a positive HCV test between 2001 and 2015, 42 
patients chronic HCV infections were re-identified. However, in only one of these 
patients HCV infection could be attributed to unsafe sexual activities, as most patients 
were infected through (former) IVDU (76%)53. However, within the Swiss HCVree trial, 
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screening of 3722 of 4257 HIV-positive MSM for HCV RNA between October 2015 and 
May 2016, revealed 177 patients with an undiagnosed ongoing HCV infection of whom 
24 had an acute HCV infection54. Furthermore, a Dutch modelling study showed that an 
increased frequency of screening with HCV PCR, targeted at a group of previously 
infected patients and in combination with immediate DAA therapy, could positively 
affect the HCV epidemic among HIV-positive MSM in a cost-effective way55. Future 
studies should look at inventive ways to diagnose HCV infections early in high-risk MSM.  
 
4. The high reinfection rate among HIV-positive MSM is a major problem16,56. The 
reinfection rate (secondary incidence) is higher than the primary incidence (Chapter 7). 
Besides raising awareness among the total HIV-positive MSM population (primary 
prevention), behavioral interventions should be specifically targeted at HCV-infected 
HIV-positive MSM (secondary prevention). Modeling showed that behavioral 
interventions can have a large impact on the prevalence and incidence of HCV among 
the HIV positive MSM population23. For HIV infection, a Cochrane review and meta-
analysis, in which 40 studies on behavioral interventions regarding sexual risk behavior 
among HIV-negative MSM were analyzed, showed that behavioral interventions in this 
group can lead to a significant reduction in number of partners and/or a reduction in 
unprotected anal sex57. However, it is not known whether these interventions will be as 
effective in HIV-positive MSM. A recent qualitative study among 20 Dutch HIV-infected 
MSM showed that a low level of perceived self-efficacy (an individual's belief in their 
innate ability to achieve goals) was a prominent barrier to behavioral change and that 
this was directly influenced by drug-use (Chemsex). More research should be focused 
on behavioral change in MSM at risk for HCV reinfection.   
 
5. DAA are quite expensive and therefore under mining the sustainability of health care 
systems. Although Popping et al. showed that acute DAA therapy could be cost-
effective in the setting of Dutch HIV-positive MSM, this does not mean that the 3 or 5-
year budget impact is affordable within our healthcare system. For the Netherlands, 
there is no maximal affordability threshold. The affordability of costly drugs is improved 
through price negations and price/volume arrangements with the pharmaceutical 
industry until the budget impact and ICER are acceptable (with a cost-effectiveness 
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threshold of 80.000/QALY)58. As spontaneous clearance among HIV-positive MSM is 
low, most acutely infected men will continue to be treated for chronic HCV infection. 
Expanding reimbursement criteria for acute HCV infection for this subgroup will 
probably not lead to unaffordable rise of the budget impact of this intervention, thus its 
implementation should be on the political agenda. Nonetheless, the high costs of DAA’s 
and their budget impact are still a global concern as it forbids equal access to therapy, 
especially in middle and low income countries, even after voluntary licencing59.   
 
6. Although resistance-associated substitions (RAS) did not play a major role in the clinical 
trials in this thesis (Chapter 2 and chapter 3), Newsum et al. showed that both the NS3 
Q80K polymorphism and the NS5B S282T RAS, resp. associated with simeprevir and 
sofosbuvir resistance, were found in Dutch MSM-specific clusters19,60. As discussed in 
Chapter 4, RAS prevalence can be subtype or key population specific. Efforts should be 
undertaken to systematically monitor RAS frequencies within initiatives like HEPCARE 
(an European HCV program to monitor resistance to direct-acting antiviral agents in real 
life61) in an attempt to, in the case of newly emergent RAS with high resistance to 
therapy, adjust treatment accordingly before they possibly becomes widespread.   
 
Factors that (can) positively influence HCV elimination among Dutch HIV-positive MSM 
 
1. The HCV care continuum among HIV-positive MSM is interwoven with already existing 
and well-developed HIV care continuum. Therefore, HCV care for HIV-positive MSM is 
nationally organized and monitored with tight collaboration between various partners. 
Dutch HIV-positive MSM are regularly and systematically screened for HCV infection as 
specified in the national HIV guideline (as described in Chapter 1), and, national data on 
HCV infections in this subgroup is collected through the already existing ATHENA-cohort 
(Chapter 4). This makes thigh monitoring of the HCV epidemic among Dutch HIV-
positive MSM feasible, thereby making it possible to assess the possible effects of other 
epidemiological coinciding trends. Also patient advocacy organizations are nationally 
well-organized, thereby partnering in raising patient awareness and actively involved in 
implementation of new interventions.  
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2. This thesis describes that DAA therapy can positively impact the HCV-epidemic among 
HIV-positive MSM. High treatment uptake after unrestricted access to DAA therapy for 
chronically infected MSM led to a decline in prevalence and incidence in this key 
population (treatment as prevention; Chapter 4 and 5).  
 
3. Treatment of acute HCV infection is effective, feasible and cost-effective in the setting 
of Dutch HIV-positive MSM and should be implemented to further exploit the 
treatment as prevention effect within this population (Chapter 3).  
 
4. Treatment shortening of LDP/SOF is not only possible for genotype 1. It is also possible 
for  but also for genotype 4 infected patients (without liver cirrhosis and a viral load < 
10 million IU/mL) (Chapter 2). This is important as genotype 4 is the second most 
prevalent genotype among Dutch HIV-positive MSM and as it could reduce costs and 
possibly improve adherence.  
 
Although some of these factors cannot be applied to other key populations or might not be 
effective in other settings, they seem to work for Dutch HIV-positive MSM and future 
research should focus on their possible effects in different key populations or different local 
settings. 
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